  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].   
 
 
 
 
 
Phase II trial of nivolumab with chemotherapy as 
neoadjuvant treatment in inflammatory breast cancer (IBC)  
 
 
 
 
 
  Regulatory Sponsor/  
  Principal Investigator:               [INVESTIGATOR_556424], MD  
                                                      Assistant Professor  of Medicine  
           NYU Perlmutter Cancer Center  
       [ADDRESS_730866], Fourth Floor  
       [LOCATION_001], NY [ZIP_CODE]  
       Tel: (212) 731 -6364  
       Email: maryann.kwa@nyu langone .org 
 
  
Funding Sponsor:  Bristol -Myers Squibb , Inc 
 
Study Product:  Nivolumab (Opdivo®) 
 
Protocol Number:  CA209 -8NL 
 
IND Number:  141788    
 
Study Number:           s17-[ZIP_CODE]  
 
Study Registry ID: [REMOVED]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Clinical Research Protocol  

S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  ii  
 
 
Coordinating Center:  
Laura & Isaac Perlmutter Cancer Center / NYU Langone Health  
Clinical Trials Office  
PCC -[EMAIL_10577]  
 
Participating sites:  
1. Laura & Isaac Pe rlmutter Cancer Center  / NYU Langone Health  
2. Bellevue Hospi[INVESTIGATOR_307]  
3. Indiana University  
 
ClinicalTrials.gov Number:   [STUDY_ID_REMOVED]  
 
Initial version:  BMS  7/13/2018   
Protocol Development & Progress Monitoring Unit  / Clinical Trials Office  10/4/ 2018 
FDA 11/28/2018  
PRMC 1/ 4/2019  
 
Amended: 06/11/2019  
Amended: 2/4/2020  
Amended: 8/ 4/2020  
Amended: 10/1/20  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  iii  
 
 
 
PROTOCOL APPROVAL SIGNATURES  
 
 
Protocol Title:  PHASE II TRIAL OF NIVOLUMAB WITH CHEMOTHERAPY AS NEOADJUVANT 
TREATMENT IN INFLAMMATORY BREAST CANCER (IBC)  
 
 
Protocol Number: s17-[ZIP_CODE]  
 
This study will be conducted in compliance with the clinical study protocol (and amendments),  
International Conference on Harmonisation of Technical Requirements for Registration of  
Pharmaceuti cals for Human Use guidelines for current Good Clinical Practice, and applicable  
regulatory requirements.  
 
 
 
        
Signature  
 
        
[CONTACT_1782]  
  
S17-[ADDRESS_730867] Cancer (IBC) and Current Therapi[INVESTIGATOR_014]  ................................ .....................  3 
1.1.2  IBC Biology and PD -L1 Express ion ................................ ................................ .........................  4 
1.1.3  Study Rationale and Hypothesis  ................................ ................................ ..............................  5 
1.2 INVESTIGATIONAL AGENT  ................................ ................................ ................................ ....................  5 
1.2.1   NIVOLUMAB AND MECHANISM OF ACTION  ................................ ................................ ............................  5 
1.2.2  PRECLINICAL DATA FOR NIVOLUMAB  ................................ ................................ ................................ ... 5 
1.2.3   NIVOLUMAB PHARMACOKINETIC DATA IN HUMANS  ................................ ................................ ...............  5 
1.2.4   NIVOLUMAB CLINICAL EFFICACY ................................ ................................ ................................ ..........  6 
1.2.5   NIVOLUMAB CLINICAL SAFETY  ................................ ................................ ................................ .............  6 
1.3 CLINICAL DATA TO DATE ................................ ................................ ................................ .....................  7 
1.3.1  Combined Modality Treatment with Anthracycline -based Chemotherapy in IBC  ....................  7 
1.3.2 Addition of Taxanes to Preoperative Systemic Therapy in IBC  ................................ ...............  7 
1.3.3 Targeted Therapi[INVESTIGATOR_44980]2 -positive IBC  ................................ ................................ ...............  8 
1.3.4 Neoadjuvant Treatment with Bevacizumab in IBC  ................................ ................................ .. 9 
1.3.5 Neodjuvant Therapy with Carboplatin in TNBC  ................................ ................................ ..... 10 
1.3.6 Neoadjuvant Therapy with Anti -PD-1/PD -L1 Antibodies in TNBC  ................................ ........  10 
1.3.7 Treatment with Anti -PD-1/PD -L1 Antibodies in HER2 -positive Advanced Breast Cancer  .... [ADDRESS_730868] Ongoing Neoadjuvant Studies in IBC  ................................ ................................ .........  12 
1.4 DOSE RATIONALE AND SCHEDULE  ................................ ................................ ................................ ..... 13 
1.4.1  RATIONALE FOR NIVOLUMAB DOSE AND SCHEDULE  ................................ ................................ ...........  16 
1.4.2  RATIONALE FOR CHEMOTHERAPY DOSE AND SCHEDULE  ................................ ................................ .... 16 
1.5 RESEARCH RISKS & BENEFITS  ................................ ................................ ................................ ..........  [ADDRESS_730869] RECRUITMENT /SCREENING AND CLINICAL PROCEDURES /ASSESSMENTS  ..............................  23 
4.3.1  Informed Consent  ................................ ................................ ................................ ......................  24 
4.3.2 Documentation of Consent  ................................ ................................ ................................ ........  25 
4.3.3  Multi -Site Surveillance ................................ ................................ ................................ ...............  25 
4.3.4 Patient Informed Consent at Additional Sites  ................................ ................................ ............  25 
4.3.5  Inclusion/Exclusion Criteria  ................................ ................................ ................................ ....... 25 
4.3.6  Medical History  ................................ ................................ ................................ ..........................  25 
4.3.7  Prior Medications  ................................ ................................ ................................ ......................  25 
4.3.8  Concomitant Medications  ................................ ................................ ................................ ..........  25 
4.3.9  Disease Details  ................................ ................................ ................................ .........................  25 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  v 4.3.10   Adverse Event (AE) Monitoring ................................ ................................ ...............................  26 
4.3.11  Full Physical Exam  ................................ ................................ ................................ ...................  26 
4.3.12  Directed Physical Exam  ................................ ................................ ................................ ..........  26 
4.3.1 3  Vital Signs  ................................ ................................ ................................ ...............................  26 
4.3.1 4  Eastern Cooperative Oncology Group (ECOG) Performance Status ................................ ..... 26 
4.3.1 5 Collection of Tumor Tissue Prior To Treatment  ................................ ................................ ....... 26 
4.3.1 6  Tumor Imaging /Cardiac Imaging ................................ ................................ .............................  26 
4.3.1 7  Laboratory Procedures/Assessments  ................................ ................................ .....................  [ADDRESS_730870] Preparation  ................................ ................................ ................................ ...... 29 
5.1.3  Recommended Storage and Use Conditions  ................................ ................................ ........  29 
5.2 TREATMENT REGIMEN  ................................ ................................ ................................ ......................  29 
5.2.1 Treatment  of Nivolumab -Related Infusion Reactions  ................................ ............................  30 
5.3 DOSAGE MODIFICATION  ................................ ................................ ................................ ....................  31 
5.3.1  Nivolumab Dose Delay Criteria for Study Treatment  ................................ .............................  31 
5.3.2 Criteria for Discontinuation of Nivolumab  ................................ ................................ ..............  32 
5.3.3 Criteria To Resume Treatment with Nivolumab  ................................ ................................ ..... 33 
5.3.4 Recommendations for Chemotherapy Delays and Modifications  ................................ ..........  33 
5.4 PREPARATION /HANDLING /STORAGE /ACCOUNTABILITY  ................................ ................................ ....... [ADDRESS_730871] TREATMENT COMPLIANCE MONITORING  ................................ ................................ ..............  37 
5.6 CONCOMITANT THERAPY  ................................ ................................ ................................ ..................  37 
5.6.1 Prohibited Therapi[INVESTIGATOR_556425]  ................................ ................................ ....................  39 
5.6.2 Permitted Therapi[INVESTIGATOR_556425]  ................................ ................................ .....................  39 
6 STUDY PROCEDURES  ................................ ................................ ................................ ......................  38 
6.1 STUDY CALENDAR /STUDY SCHEDULE OF EVENTS  ................................ ................................ ..............  [ADDRESS_730872]-TREATMENT FOLLOW -UP/END OF TREATMENT /END OF STUDY VISITS ................................ ....... [ADDRESS_730873]-Study Access  ................................ ................................ ................................ .................  46 
6.5 CORRELATIVE STUDIES ................................ ................................ ................................ .....................  46 
6.5.1 Tumor Tissue Samples  ................................ ................................ ................................ ..........  46 
6.5.2 Characterization of Tumor I mmune Cells ………… …………………………………………….. [ADDRESS_730874] POPULATION (S) FOR ANALYSIS  ................................ ................................ ...........................  49 
8 SAFETY AND ADVERSE EVENTS  ................................ ................................ ................................ ... 50 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  vi 8.1 DEFINITIONS  ................................ ................................ ................................ ................................ ..... 50 
8.2 RECORDING OF ADVERSE EVENTS  ................................ ................................ ................................ .... 52 
8.3 REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBL EMS ................................ ..... 52 
8.3.1  Investigator Reporting: Notifying the Study Sponsor  ................................ .............................  53 
8.3.2 Pregnancy  ................................ ................................ ................................ ..............................  55 
8.3.3  Overdose  ................................ ................................ ................................ ................................  57 
8.3.4  Other Safety Considerations  ................................ ................................ ................................ .. 57 
8.3.5  Investigator Reporting: Notifying the IRB  ................................ ................................ ...............  57 
8.3.6  Sponsor Reporting: Notifying the FDA  ................................ ................................ ...................  58 
8.3.7 Sponsor Reporting: Notifyin g Participating Investigators  ................................ ......................  59 
8.4 MEDICAL MONITORING  ................................ ................................ ................................ ......................  59 
8.4.1  Data Safety Monitoring Committee (DSMC)  ................................ ................................ ..........  [ADDRESS_730875] OF TABLES  
Table 1 : Select ongoing neoadjuvant studies in IBC ………………………………………………………..…..12  
Table 2 : Treatment dose and schedule for Cohort 1 ………………………………………………………..….. 14 
Table 3 : Treatment schedule for Cohort 1 …………………………………………………………………….....14  
Table 4 : Treatment dose and sched ule for Cohort 2 ……………………………………………………………15  
Table 5:  Treatment schedule for Cohort 2 ……………………………………………………………………... ..15 
Table 6:  Adequate organ function laboratory value s…………………………………………………………...2 1 
Table 7 : Dose modification levels for docetaxel/ paclitaxel ……. .………….…………………………….…….33  
Table 8 : Dose modifications for taxane -related neurosensory toxicity ……………………………….............33  
Table 9 : Dose modifications for taxane -related musculoskeletal pain not controlled by [CONTACT_25703] .….……34  
Table 10 : Dose modification  levels for doxorubicin/ cyclophosphamide   ……..………………………… .......34 
Table 11 : Dose modifications and delays for docetaxel/ paclitaxel/ doxorubicin / cyclophosphamid e..…..34  
Table 1 2: Left ventricular systolic dysfunction ……………………………………………………………….. …[ADDRESS_730876] Cancer Trialists' Collaborative Group  
EC Epi[INVESTIGATOR_556426] 5-fluorouracil, doxorubicin, and cyclophosphamide  
FEC 5-fluorouracil, epi[INVESTIGATOR_14962], and cyclophosphamide  
FDA [LOCATION_002] Food and Drug Administration  
FFPE  Formalin fixed paraffin embedded  
FISH  Fluorescence in situ hybridization  
S17-[ADDRESS_730877] ratio  
HR Hormone receptor  
IB Investigator’s Brochure  
IBC Inflammatory Breast Cancer  
ICF Informed consent form  
IFN Interferon  
IHC Immunohistochemistry  
INR Internationalized Normalized Ratio  
IP Investigational product  
irAESI  immune related adverse events  of special interest  
IRB Institutional Review Board  
IRFI Invasive recurrence -free survival  
IV Intravenous  
Kg Kilogram  
L Liter 
LDH Lactate dehydrogenase  
LFT Liver function test  
LVEF  Left ventricular ejection fraction  
LVSD  Left ventricular systolic dysfunction  
MDACC  MD Anderson Cancer Center   
mcL Microliter  
Mg Milligram  
MP Multiplexing  
MRI Magnetic resonance imaging  
mRNA  Messenger ribonucleic acid  
MUGA  Multigated acquisition  
N Number  
NCI National Cancer Institute  
NCT ClinicalTrials.gov registry number  
NGS  Next generation sequencing  
NSCLC  Non-small cell lung cancer  
NYUL H NYU Langone Health   
ORR  Overall response rate  
OS Overall survival  
PCC  NYU Perlmutter Cancer Center  
pCR Pathologic complete response  
PCR  Polymerase chain reaction  
PD Progression of disease  
PD-1 Programmed cell death -1 
PD-L1 Programmed cell death -ligand 1  
PD-L2 Programmed cell death -ligand 2  
PET Positron Emission Tomography  
PFS Progression -free survival  
PI [INVESTIGATOR_556427] (s)  
PR Partial response  
PR Progesterone receptor  
S17-[ADDRESS_730878] in the 
heart's electrical cycle  
QTc QT interval corrected for heart rate  
RCC  Clear -cell renal cell carcinoma  
SAE Serious adverse event  
SD Stable disease  
T Tumor  
TBD To be determined  
T-DM1  Ado-trastuzumab emtansine  
TFT Thyroid function test  
TIL Tumor infiltrating lymphocytes  
TMB  Tumor mutation burden  
TNBC  Triple negative breast cancer  
TTE Transthoracic echocardiogram  
UC Urothelial carcinoma  
ULN Upper limit of normal  
VEGF  Vascular endothelial growth factor  
VP Vincristine and prednisone  
Vss Volume of distribution at steady state  
S17-[ADDRESS_730879] cancer (IBC)  
Brief Summary  Study of efficacy  of nivolumab with neoadjuvant chemotherapy  in patients with 
IBC  
Protocol Number  CA209 -8NL  
Study Number  S17-[ZIP_CODE]  
Phase  Phase II 
Methodology  Multi -center open label , phase II study  
Study Duration  6 years  
Participant Duration  Up to 24 months  
Study Center(s)  Multi -center: NYU Perlmutter Cancer Center, Bellevue Hospi[INVESTIGATOR_556428]  
• To determine whether the addition of nivolumab to chemotherapy 
improves pathologic complete response (pCR) in the breast and post -
therapy lymph nodes eva luated histologically (ypT0/Tis ypN0) in 
patients with inflammatory breast cancer  (IBC) . 
 
Secondary Objectives  
• To evaluate the safety and tolerability of the combination of nivolumab 
with neoadjuvant chemotherapy  in IBC.  
• To evaluate the i nvasive recurrence -free interval (IRFI) [time  frame:  up 
to 24 months after study entry].   
 
Correlative Studies  
• To explore predictive markers of response/sensitivity as well as 
markers of resistance to therapy.  
• To assess the frequency of mutational and neoantigen load and to 
explore mutational and neoantigen load as predictive markers of 
response.  
• To assess changes in expression levels of biomarkers or biomarker 
panels before, during , and after treatment.  
  
Number of Subjects  52 
Diagnosis and Main 
Inclusion Criteria  Patients >[ADDRESS_730880] cance r subtypes  are allowed:  
 
 Triple negative breast cancer (TNB C) 
 Hormone receptor (HR) -positive and human epi[INVESTIGATOR_13392] 2 ( HER2) -negative  
 HR-positive  or HR-negative and HER2 -positive    
 
S17-[ADDRESS_730881], 
Dose, Route   
Cohort 1: TNBC or HR-positive/HER2 -negative : (n=26)  
 
1. Cycle 1 -4, 21 day cycle  
• Nivolumab 360 mg IV on Day 1 x 4 cycles and Paclitaxel 80 mg/m2 IV 
on Day 1, 8, and 15 x 4 cycles, followed by  
2.  Cycle 5 -8, 14 day cycle  
• Doxorubicin 60 mg/m2 IV on Day 1 x 4 cycles and Cyclophosphamide 
600 mg/m2 IV on Day 1 x 4 cycles  
 
Cohort 2: HR -positive/HR -negative and HER2 -positive : (n=26)  
 
1. Cycle 1 -4, 21 day cycle  
• Nivolumab 360 mg IV on Day 1 x 4 cycles, + Docetaxel* 75 mg/m2 IV 
on Day 1 x 4 cycles, + Trastuzumab ** 8 mg/kg IV on Da y 1 of Cycle 1 
and then 6 mg/kg IV on Day 1 of Cycle 2 -4, + Pertuzumab 840 mg IV 
on Day 1 of Cycle 1 and then 420 mg IV on Day 1 of Cycle 2 -4, 
followed by  
2. Cycle 5 -8, 14 day cycle  
• Doxorubicin 60 mg/m2 IV on Day 1 x 4 cycles and Cyclophosphamide 
600 mg/m2 IV on Day 1 x 4 cycles  
 
*Paclitaxel 80 mg/m2 IV weekly x 12 (Cycle 1 -4) may be substituted  
**Trastuzumab biosimilar may be used   
 
Statistical Analysis  Summary statistics (percentage, mean, standard deviation, etc.) will be 
provided for the safety endpoints as appropriate.  Sequential boundaries will 
be used to monitor dose -limiting toxicity rate. There will be an interim safety 
analysis in Cohort  2.  Monitoring for toxicity will follow a Bayesian -based rule 
for the probability that the rate of DLT exceeds  a maximal tolerated level of 
30%. We will assume a Beta(1,2) prior, which is prior information equivalent to 
one DLT observed in three treated patients.  
 
The association between biomarkers and best overall response (responder 
versus non -responder primary) will be described by [CONTACT_556465], and assessed using the mid -p adju stment to Fisher’s exact test. 
The association between biomarkers and response will be described by 
[CONTACT_556466] a two -sample t -test with 
transformation as needed . 
 
 
S17-[ADDRESS_730882] Cancer (IBC) and Current T herapi[INVESTIGATOR_556429] (IBC) is the most aggressive form of breast cancer, and the incidence in the 
[LOCATION_002] ranges from 1 to 5%1. IBC is a clinical presentation that is characterized by [CONTACT_556467], 
rapid enlargement of the breast, and a characteristic peau d ’orange appearance of the skin2.  Pathologically, 
tumor emboli are often present in dermal lymphatics of the involved skin, however dermal lymphatic 
involvement itself is not required for a diagnosis of IBC.  IBC is chara cterized by [CONTACT_556468], 
rapid disease progression, local and distant metastases, and worse overall survival (OS) when compared 
to non -IBC. The prognosis rema ins poor, with a 5 -year OS of approximately 50 %3, despi[INVESTIGATOR_556430].  The median OS duration of patients with IBC compared to those with non -IBC tumors for stage 
III disease is 4.75 years versus 13.40 years,4 and for stage IV disease, it is 2.27 years versus 3.40 years5. 
IBC is usually hormone receptor (HR) -negative and is more frequently human epi[INVESTIGATOR_13392] 2 ( HER2) -positive compared to the more common ductal breast cancer.  Gene expression profiling 
studies of IBC have shown a greater  frequency of basal and HER2 overexpression.  
The multidisciplinary approach to treatment of IBC without distant metastases involves neoadjuvant 
(primary) systemic chemotherapy followed by [CONTACT_556469]6,7.  Before the use of systemic chemotherapy, the 5 -year OS rate using surgery 
and/or radiatio n therapy ranged from 0 to 5%.  After the introduction of combination chemotherapy as part  
of a multimodality approach, survival has improved, with 15 -year OS in 20% -30% of patients. Because IBC 
is a rare disease, there are no large randomized trials evaluating the optimal preoperative systemic therapy. 
The current systemic therapy recommendati ons are based on results from retrospective studies, small er 
prospective studies, and data from locally advanced non -inflammatory breast cancer. A retrospective 
analysis demonstrated the benefit of preoperative systemic therapy followed by [CONTACT_556470] -free survival 
(DFS) were reported for the combined modality approach8.  A large retros pective study of patients with IBC 
at The University of [LOCATION_007] MD Anderson Cancer Center (MDACC) showed that initial treatment with 
anthracycline -based chemotherapy followed by [CONTACT_193385] —with r adiation, mastectomy, or both —and 
additional post -operative chemotherapy resulted in a 15 -year DFS rate  of 28%9.   
 
Achieving a pathologic complete response (pCR) to neoadjuvant therapy is associated with favorable 
outcomes in earlier stage breast cancer.  A retrospective study demonstrated that the addition of a taxane 
to an anth racycline -based chemotherapy regimen improved progression -free survival ( PFS) and OS in 
patients with hormone receptor (HR) -negative IBC10.  A study of patients with IBC and metastasis to axillary 
lymph nodes who were treated with anthracycline -based chemotherapy with or without taxanes revealed 
that more patients receiving the combination achieved a pCR compared to those that only received 
anthracycli ne-based chemotherapy11.  Furthermore, those with a pCR in the axillary lymph nodes had 
improved DFS and OS compared to those with residual axillary disease.   
For the initial treatmen t of patients with IBC, preoperative systemic therapy with an anthracycline -based 
regimen with taxane is recommended.  For patients with HER2 -positive IBC, the addition of trastuzumab to 
systemic chemotherapy is associated with improvement in response rate s.  A prospective study that 
randomized patients with locally advanced breast cancer, including IBC, to neoadjuvant anthracycline -
based chemotherapy with or without trastuzumab for one year demonstrated that the addition of 
trastuzumab significantly improv ed overall response rate (ORR) and event free survival12,13.  The inclusion 
of trastuzumab in the chemotherapy regimen is recommended for patients with HER2 -positive IBC.  In 
addition, a phase II trial of patients with HER2 -positive breast cancer including IBC showed improvement 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  4 in pCR with the addition of another HER2 -targeting agent, pertuzumab14.  Pertuzumab may therefore be 
included in the preoperative systemic therapy in patients with HER2 -positive IBC.  All patients with HR -
positive IBC are recommended to receive endocrine therapy sequentially after completion of planned 
preoperative systemic therapy and surgery.   
 
The res ponse to preoperative chemotherapy is an important prognostic factor.  A retrospective analysis at 
MDACC  looked at  treatment efficacy in 527 patients with IBC by [CONTACT_84888] - and H ER2-defined subtypes15.  The 
patients had received neoadjuvant chemotherapy, and the overall pCR rate was 15.2%.  Based on subtype, 
the pCR rates were 7.4% in HR -positive/HER2 -negative, 12.4% in triple negative breast cancer (TNBC), 
15% in HR -positive/HER2 -positive, and 30.5% in HR -negative/HER2 -positive15. Features that were 
associa ted with improvement in DFS and OS were achieving a pCR, no evidence of vascular invasion, non -
TNBC subtype, and adjuvant hormonal therapy and radiotherapy.  
 
In summary, n eoadjuvant systemic therapy, modified radical mastectomy and axillary lymph node 
dissection, post -mastectomy radiotherapy, adjuvant targeted therapy (as indicated) and hormonal therapy 
(as indicated) are  the current recommended multimodality treatment s for IBC6,7, however pCR rates are 
low and overall outcomes are poor, signifying an important need for better therapi[INVESTIGATOR_014].   
 
1.1.[ADDRESS_730883] documented a higher frequency of negative HR status in IBC tumors compared to 
non-IBC tumor s, with some reporting up to 50%  of tumors being estrogen receptor (ER) -negative16.  Lack  
of expression of hormone rec eptors has been shown to be associated with a more aggressive clinical 
course and decreased breast cancer -specific and overall survival.  A higher incidence of HER2 -positive 
tumors has also been reported among IBC17. Tumor infiltrating lymphocytes (TILs) have been shown to be 
prognostic in the more highly proliferative and aggressive breast cancer subtypes, such as TNBC  which 
lacks ER/PR expression, and HER2 -positive breast cancer18-20.  The degree of infiltrating immune cells in 
the tumor microenvironment has correlated with response to treatment and clinical outcome in these two 
subtypes, providing important prognostic and possibly  predictive inf ormation. IBC comprises similar 
molecular subtypes as other types of breast cancer, but may contain a more important role for the tumor 
microenvironment, including immune cell infiltration21.  
 
Advances in cancer immunotherapy and a growing body of research have focused on the role of the 
antitumor response in breast cancer. There is strong evidence that TILs have prognostic value and are 
associated with clinical outcome and improved survival. Immunotherapy studies have focused on the role 
of the programmed cell death -1 (PD -1) receptor/programmed death -ligand 1 (PD -L1) pathway in 
maintaining immunosuppression in the tumor microenvironment.   PD-1 is a member of the T -cell co -
regulatory receptor family and, when it binds to its ligands, PD -L1 and PD -L2, it attenuates T -cell functi on, 
survival, and expansion, thereby [CONTACT_556471]. PD -L1 is expressed on activated T cells 
within the tumor microenvironment; however, tumors can also express PD -L1, which has been 
demonstrated in breast cancer, melanoma, lung cancer, and ren al cell cancer, among other malignancies.  
This expression of PD -L1 enables inhibition of the local immune response. Blockade of the PD-1/PD -L1 
axis has emerged as a promising therapeutic option to enhance antitumor immunity and is actively being  
investiga ted in breast cancer, in particular TNBC,  with encouraging results.  Atezolizumab (an anti -PD-1 
antibody), in combination with nab -paclitaxel, was recently granted accelerated approval by [CONTACT_556472] -L122. 
 
A study analyzed PD -L1 mRNA expression in [ADDRESS_730884] cancer tumor samples, i ncluding 112 samples 
from IBC23. IBC patients were younger than non-IBC patients and tumor samples were more often 
associated with poor prognosis features: higher grade and stage, ER and progesterone ( PR)-negative, 
HER2 -positive and aggress ive molecular subtypes (basal, HER2 -enriched).  The 5 -year metastasis -free 
survival was 49% (95% confidence interval [ CI]: 37–64%) in IBC patients and 82% ( 95% CI: 76 –88%) in 
non-IBC patients ( p= 2.7E -9; log -rank test).  Of the IBC samples, the frequency o f PD -L1 mRNA 
overexpression was 38% (42 of 112), and in comparison, 28% of non -IBC samples showed PD -L1 
overexpressio n.  In IBC, PD -L1 expression was associated with ER -negative status, basal and HER2 -
enriched subtypes, as well as CD8+ T-cell specific gene  signatures.  Pathologic response to neoadjuvant 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  5 anthracycline -based chemotherapy was found in 66 out of 112 patients with IBC, of which 22 (33%) had 
achieved pCR.  Expression in tumors (T) was measured as discrete value after comparison with mean 
expression in normal breast samples (NB): overexpression, designated as ‘PD -L1-high’, was defined by a 
T/NB ratio ≥ 2 and no overexpression, or ‘PD -L1-low’, was designated by a T/NB ratio <2.  Higher PD -L1 
expression correlated with improved pathological re sponse to neoadjuvant anthracycline -based 
chemotherapy (pCR rate was 50% in the ‘PD -L1 high’ group and 20% in the ‘PD -L1 low’ group). Tumors 
with high PD -L1 expression also showed a more dense T -cell infiltration, with positive correlation between  
PD-L1 expression and the presence of elevated TILs, higher expression of T -cell-specific and CD8+ T -cell-
specific gene expression signatures, and higher expression of genes coding proteins related to the T -cell 
receptor .   
 
1.1.[ADDRESS_730885] cancer.  Blockade of the PD -1/PD -L1 axis has 
emerged as a promising option to enhance anti -tumor im munity and clinical responses.  PD-L1 expression 
in IBC is frequent and may predict for improved response to chemotherapy and should be investigated in 
the neoadjuvant setting.  Achieving a pCR to neoadjuvant therapy is associated with favorable disease -free 
survival and OS.   We hypothesize  that PD -[ADDRESS_730886] 
neoadjuvant (primary) systemic chemotherapy will be well tolerated and will increase the rate of pCR and 
reduce risk of recurrence  in patients with IBC compared to known efficacy of neoadjuvant ch emotherapy 
alone.   
1.2 Investigational Agent  
1.2.1  Nivolumab and Mechanism of Action  
 
Nivolumab (also referred to as BMS -936558, MDX1106, or ONO -4538) is a human monoclonal antibody 
(HuMAb; immunoglobulin G4 [IgG4] -S228P) that targets the PD-1 cluster  of differentiation 279 (CD279) cell 
surface membrane receptor. PD -1 is a negative regulatory molecule expressed by [CONTACT_93247] T and B 
lymphocytes24. Binding of PD -1 to it s ligands, PD-L1 and PD -L2, results in the down regulation of 
lymphocyte activation. Inhibition of the interaction between PD -1 and its ligands promotes immune 
responses and antigen -specific T -cell responses to both foreign antigens as well as self -antigens . 
OPDIVOTM (nivolumab) is approved for the treatment of several types of cancer and is also being 
investigated in various other types of cancer as monotherapy or in combination with other therapi[INVESTIGATOR_014] . 
 
1.2.2  Preclinical D ata for Nivolumab  
 
Nivolumab has bee n shown to bind specifically to the human P D-1 receptor and inhibits the intera ction of 
PD-1 with its ligands, PD-L1 and PD -L2, resulting in enhanced T -cell proliferation and interferon -gamma 
(IFN-γ) release in vitro.25-27 Nivolumab binds with high affinity to activate d human T -cells expressing cell 
surface PD -1 and to cynomolgus monkey PD -1. In a m ixed lymphocyte reaction, nivolumab promoted a 
reproducible concentration -dependent enhancement of IFN - release28. In intravenous repeat -dose 
toxicology studies in cynomol gus monkeys, nivolumab was well tolerated at doses up to 50 mg/kg, 
administered weekly for 5 weeks, and at d oses up to 50 mg/kg administered twice weekly for 27 doses. In 
addition, an enhanced pre - and postnatal development study in pregnant cynomolgus monkeys with 
nivolumab was conducted29.  Administration of nivolumab at up to 50 mg/kg 2QW was well  tolerated by 
[CONTACT_162621].  
 
1.2.3   Nivolumab Pharmacokinetic Data in H umans  
 
The pharmacokinetics (PK), clinical activity, and safety of nivolumab have been assessed in  subjects with 
non-small cell lung cancer (NSCLC) , melanoma, clear -cell renal cell carcinoma  (RCC), classical Hodgkin 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  6 Lymphoma (cHL), urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (SCCHN), in 
addition to other tumor types. Nivolumab monotherapy is approved in  the [LOCATION_002]  for unresectable or 
metastatic melanoma, previously treated metastatic NSCLC, previously treated recurrent or metastatic 
SCCHN, previously treated advanc ed RCC, previously treated relapsed or refractory cHL, and previously 
treated advanced or metastatic UC . In addition, nivolumab has been approved for use in combination with 
ipi[INVESTIGATOR_556431] . Nivolumab is being investigated both as mono therapy and in 
combination with chemotherapy, targeted therapi[INVESTIGATOR_014], and other immunotherapi[INVESTIGATOR_556432].  
 
The PK of nivolumab was studied in subjects with cancer over a dose range of 0.1 to 20 mg/kg  administered 
as a singl e dose or as multiple doses of nivolumab every 2 or 3 weeks. Nivolumab  clearance (CL) decreases 
over time, with a mean maximal reduct ion (% coefficient of variation [CV%]) from baseline values of 
approximately 24.5% (47.6%) resulting in a g eometric mean steady state clearance (CLss) (CV%) of 8.2 
mL/h (53.9%); the decrease in CLss is not considered clinically relevant. The geometric mean volume of 
distribution at steady state (Vss) was 6.8 L (27.3%), and geometric mean elimination half -life (t1/2) was 25 
days (77.5%). Steady -state concentrations of nivolumab were reached by 12 weeks when administered at 
3 mg/kg Q2W, and systemic accumulation was approximately 3.7 -fold. The exposure to nivolumab 
increased dose proportionally over the dose range of 0.1 to 10 mg /kg administered every [ADDRESS_730887] on the CL of nivolumab: age (29 to 87 years), gender, race, baseline LDH, PD -L1 
status, solid tumor type, baseline tumor size, and hepatic impairment.  
 
PPK and exposure response analyses have been performed to support use of nivolumab 240 mg Q2W, 
360 mg Q3W,  and 480 mg Q4W dosing regimens in subjects with cancer in addition to the 3 mg/kg Q2W 
regimen. A flat dose of nivolumab 240 mg Q2W was selected since it is identical to a dose of 3 mg/kg for 
subjects weighing 80 kg, the observed median body wei ght in nivolumab treated cancer patients, while the 
nivolumab 360 mg Q3W and 480 mg Q4W regimens allow flexibility of dosing with less frequent visits and 
in combination with other agents using alternative dosing schedules to Q2W.   
 
Using a PPK model, the  overall distributions of nivolumab exposures (Cavgss, Cminss, Cmaxss, and 
Cmin1) are comparable after treatment with either nivolumab 3mg/kg or 240 mg Q2W. Following nivolumab 
360 mg Q3W and 480 mg Q4W, Cavgss are expected to be similar to those following  nivolumab 3 mg/kg 
or 240 mg Q2W, while Cmi nss are predicted to be 6% and about 16% lower, respectively, and are not 
considered to be clinically relevant. Following nivolumab 360 mg Q3W and 480 mg Q4W, Cmaxss are  
predicted to be approximately 23% and about  43% greater, respectively, relative to that following nivolumab 
3 mg/kg Q2W dosing. However, the range of nivolumab exposures (median and 90% prediction intervals) 
following administration of 240 mg flat Q2W, 360 mg Q3W, and 480 mg Q4W regimens across the  35 to 
160 kg weight range are predicted to be maintained well below the corresponding exposures observed with 
the well tolerated 10 mg/kg nivolumab Q2W dosing regimen .   
 
1.2.[ADDRESS_730888] studies are ongoing and, as such, the safety profile of nivolumab combinations  continues 
to evolve.  
1.3 Clinical Data to Date  
 
1.3.1  Combined Modality T reatment  with Anthracycline -based C hemotherapy in IBC  
 
Between May 1973 and September 1993, 178 previously untreated patients with IBC without distant 
metastasis were treated at MDACC by a com bined -modality approach under four different  protocols30. Each 
protocol included induction chemotherapy, then  local therapy (radiotherapy or mastectomy), then adjuvant 
chemotherapy, and  if mastectomy was performed, adjuvant radiotherapy. Chemotherapy consisted of 5 -
fluorouracil, doxorubicin, and cyclophosphamide (FAC) with or without vincristine an d prednisone (V P). In 
one protocol , patients received an alternate adjuvant chemotherapy regimen, methotrexate and vinblastine 
(MV), if they did not achieve a  complete response ( CR) to induction chemotherapy. Results of the study  
showed that 28% of patients were currentl y free of disease beyond 15 years.  An import ant prognostic factor 
was initial response to induction chemotherapy. At 15 years, DFS  was 44% in patients who had a CR to 
induction chemotherapy, 31% in those who had a partial response (PR), and 7% in those who  had less 
than a PR.  These long -term follow -up data show that with a combi ned modality approach a signifi cant 
fraction of patients (28%) remained free of disease beyond [ADDRESS_730889], single -modality treatments 
had a  DFS of less than 5%. Therefore , using combined -moda lity treatment is recommended as a standard 
of care for IBC. 
 
1.3.2   Addition of Taxanes to Preoperative Systemic Therapy in IBC  
 
A later retrospective study at MDACC demonstrated that the addition of paclitaxel to anthracycline -based 
therapy resulted in a statistically significant improvement in outcome in patients with ER -negative IBC10.  A 
total of 240 patients tr eated between 1973 and 2000 in six  consecutive trials were included in the analysis. 
Group 1 (n = 178 ) consisted of  patients treated in the first 4 trials (1973 -1993) with FAC (5 -fluorouracil , 
doxorubicin, cyclophosphamide). Group 2 (n = 62) consisted of patients treated in th e last 2 trials (1994 -
2000) with FAC followed by [CONTACT_556473] [ADDRESS_730890] to median follow -up durations, which were 148 months (range, 85 -283 
months) in Group 1 and 45 mont hs (range, 21 -99 months) in Group 2. ER status was  negative in 58 cases 
(33%) in Group 1 and 40 cases (65%) in G roup 2. The objective response rates were similar (Group 1, 
74%; G roup 2, 82%). The median overall PFS and OS were improved in the patients trea ted with paclitaxel, 
and these differences reached statistical significance in the patients with E R-negative disease (median OS: 
Group 1, 32 months; Group 2, 54 months; p = 0.03; m edian PFS: Group 1, 18 months; Group 2, 27 months; 
p= 0.04).  
 
A systematic re view of 27 studies of IBC totaling 1232 patients found that pCR rates after no anthracycline 
induction, low -dose anthracycline induction, moderate -dose anthracycline induction, and neoadjuvant high -
dose chemotherapy subgroups were 4% (95 % CI,  1%-18%), 11% (95% CI, 7% -17%), 14% (95% CI, 8% -
22%), and 32% (95% CI, 24% -41%), respectively31.  The criteria and reporting of IBC and t reatment 
response was notably variable, with significant potential for subject heterogeneity. pCR rates appear ed to 
be related to intensity of neoadjuvant treatment.   
 
Metastases to axillary lymph nodes (ALN) is a known prognostic factor in breast cancer,  with pCR in ALN 
after chemotherapy being associated with significantly higher recurrence -free survival (RFS) and OS rates .  
A study evaluated the long-term outcome in patients with IBC achieving a pCR of cytologically proven ALN 
S17-[ADDRESS_730891] metastases. Fourteen patients (23%) achieved a pCR of the ALNs after primary chemotherapy. The 
5-year OS and RFS rates were found to be improved in those patients achieving a pCR of the ALNs (82.5% 
[95% CI, 62.8 -100],  and 78.6% [ 95% CI, 59.8 -100], respec tively, vs. 37.1% [95% CI, 25.4 -54.2] and 25.4% 
[95% CI, 15.5 -41.5], respectively) (p=0.01 [for OS] and p=0.001 [for RFS]). In addition, c ombination 
anthracycline and taxane -based primary chemotherapy resulted in significantly more patients achieving an 
ALN pCR (45% vs. 16%;  p=0.01).  
1.3.3   Targeted Therapi[INVESTIGATOR_44980]2 -positive IBC   
 
HER2 -positive IBC is associated with an overall poor prognosis17, although the introduction of HER2 -
targeting antibodies has im proved outcomes .  The phase III NOAH trial compared one year of treatment 
with trastuzumab (given as neoadjuvant and adjuvant treatment; n=117) with no trastuzumab (n=118), in 
patients with HER2 -positive locally advanced or IBC receiving neoadjuvant chemot herapy with doxorubicin, 
paclitaxel, cyclophosphamide, methotrexate, and fluorouracil13.  A total of 62 patients with IBC were 
included in the study, of which 32 patients received trastuzumab and 31 did not.  The primary endpoint was 
event -free survival  12.  The 5-year EFS was 58% (95% CI, 48–66) in the trastuzuma b group and 43% ( 95% 
CI, 34–52) in the chemotherapy alone group; the unadjusted hazard ratio (HR) for event -free s urvival 
between the two randomiz ed HER2 -positive treatment groups was 0.64 (95% CI, 0.44 -0.93; two -sided log -
rank p=0·016).  EFS was strongly associated with pCR in patients given trastuzumab. Of the 68 patients 
with a pCR (45 with trastuzumab and 23 with chemotherapy alone), the HR for EFS between those with 
and without trastuzumab was 0. 29 (95% CI , 0.11 -0.78).  Generally, patients with inflamm atory disease or 
negative hormonal receptors had a more pronounced benefit from trastuzumab.  For the patients with IBC 
who received trastuzumab, the 5 -year EFS was 64% versus 24% for those who did not receive trastuzumab 
(HR 0.34; 95% CI, 0.15 -0.80).   Th e 5-year OS for the patients with IBC was 74% versus 44%, respectively 
(HR 0.38; 95% CI, 0.15 -0.95)32. 
 
There was multicenter open -label, phase 2 neoadjuvant study (NeoSphere, [STUDY_ID_REMOVED] ), of women with 
locally advanced HER2 -positive breast cancer and IBC who were randomly assigned to receive four cycles 
of: trastuzumab plus docetaxel (group A), or pertuzumab and trastuzumab plus docetaxel (group B), or 
pertuzumab and trastuzumab (group C), or pertuzumab  plus docetaxel (group D)14.  Pertuzumab is a 
monoclocal antibody that binds to a different epi[INVESTIGATOR_556433]2 and blocks the formation of HER2 and HER3 
heterodimers.  The primary endpoint of this study was pCR in the breast.  Of  417 eligible patients, 107 were 
randomly assigned to group A (7 with IBC), 107 to group B (10 with IBC), 107 to group C (7 with IBC), and 
96 to group D (5 with IBC). Patients who were given pertuzumab and trastuzumab plus docetaxel (group 
B) had a signifi cantly improved pCR rate (49 of 107 patients; 45.8% [95% CI,  36.1-55.7]) compared with 
those given trastuzumab plus docetaxel (group A; 31 of 107; 29.0% [95% CI, 20.6 -38.5]; p=0.0141). There 
were no substantial differences in tolerability or toxicity with the addition of pertuzumab to trastuzumab and 
docetaxel, including the risk of cardiac adverse events.  The mean maximum decrease in left ventricular 
ejection fraction (LVEF) measurement was 4 -5% and was balanced across the four treatment groups. No 
signif icant change was detected when pertuzumab was added to trastuzumab and no patient had an LVEF 
decrease to less than 40% at any time during the study.   
 
The main objective of the phase II TRYPHAENA trial ([STUDY_ID_REMOVED])  was to evaluate tolerability, with a 
focus on cardiac safety, of pertuzumab plus trastuzumab in combination with standard neoadjuvant 
anthracycline -containing and anthracycline -free chemotherapy regimens in patients with HER2 -positive 
locally advanced or IBC33.  A total of 225 patients (13 with IBC) were randomized to 5-fluorouracil, 
epi[INVESTIGATOR_14962], cyclophosphamide [ FEC] followed by [CONTACT_114501] , with trastuzumab and pertuzumab starting 
either concurrent ly with FEC (Arm A) or upon initiation of docetaxel (Arm B) or to docetaxel, carboplatin , 
trastuzumab, and pertuzumab (Arm C).  The combination of trastuzumab and pertuzumab was generally 
well tolerated regardless of whether it was given sequentially or co ncomitantly with anthracycline -based  
chemotherapy , or c ombined with carboplatin -based chemotherapy.  During neoadjuvant treatment, two 
patients (2.7%; Arm B) experienced symptomatic left ventricular systolic dysfunction (LVSD) and 11 
patients (Arm A: 4 [5. 6%]; Arm B: 4 [5.3%]; Arm C: 3 [3.9%]) had declines in LVEF of ≥10% points from 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  9 baseline to <50%.  Safety outcomes at 3 years were recently reported and no new safety signals were 
identified34.    
The phase III APHINITY trial ([STUDY_ID_REMOVED]) asses sed the combination of pertuzu mab and trastuzumab 
with chemotherapy in the adjuvant setting35. The 3 -year rate  of invasive -disease -free survival were 94.1% 
in the pertuzumab group and 93.2% in the placebo group. In patients with node -positive disease, the 3 -
year rate of invasive -disease -free survival was 92.0% in the pertuzumab group, as compared with 90.2% 
in the placebo group ( HR for an invasive -disease even t, 0.77; 95% CI, 0.62 to 0.96; p = 0.02). In the cohort 
of patients with node -negative disease, the 3 -year rate of invasive -disease -free survival was 97.5% in the 
pertuzumab group and 98.4% in the placebo group ( HR for an invasive -disease even t, 1.13; 95% CI, 0.68 
to 1.86; p = 0.64).  
1.3.4  Neoadjuvant Treatment with Bevacizumab in  IBC 
IBC is molecularly associated with high vascularity, increased microvessel density, and high expression of 
angiogenic factors such as vascular endothelial growth factor (VEGF)36. Bevacizumab is a humanized 
monoclonal antibody that targets  VEGF -A. The multicenter, single -arm, phase II BEVERLY -1 study 
([STUDY_ID_REMOVED]) showed that the addition of bevacizumab to neoadjuvant and adjuv ant chemotherapy did 
not provide clinical benefit to patients with HER2 -negative IBC37.   A total of 101 patients were enrolled.  
Patients underwent 3-week treatment cycles, receiving neoadjuvant fluorouracil, epi[INVESTIGATOR_14962], 
cyclophosphamide (FEC), and bevacizumab during cycles 1 -4, then docetaxel and bevacizumab during 
cycles 5 –8.  Two to four weeks after surgery, the patients received adjuvant radiother apy, hormone therapy 
(if they had a HR -positive tumo r), and adjuvant bevacizumab. The primary endpoint was pCR in breast and 
axillary lymph nodes after neoadjuvant treatment.  After neoadjuvant therapy, 19 (19% [95% CI 12 –28]; 
p=0·16) of [ADDRESS_730892] frequent grade 3 -4 events during the neoadjuvant phase 
were neutropenia (89 [89%] of 100 patients), febrile neutropenia (37 [37%]), and mucositis (23 [23%]) and 
during the adjuvant phase the most frequent grade 3 -4 adverse event was pro teinuria (5 [7%] of 75 
patients ). Overall, the proportion of patients achieving a pCR was inferior or equal to that which has been 
reported without bevacizumab.    
Similarly, the phase 2 multicenter open label single arm BEVERLY -2 trial ([STUDY_ID_REMOVED]) evalu ated 
neoadjuvant and adjuvant bevacizumab in combination with chemotherapy for patients with HER2 -positive 
inflammatory breast cancer38.  A total of 52 patients were enrolled.  On e year of treatment with bevacizumab 
plus a trastuzumab and anthracycline -taxane -based regimen was well tolerated and 33 of 52 patients had 
a pCR (63.5%, 95% CI 49.4 -77.5). The most common adverse events were asthenia and nausea (both 
occurred in 36 [69%] of 52 patients). A total of 25 (48%) patients had grade [ADDRESS_730893] common grade 3 -4 adverse event. Only one grade 3 or worse adverse event regarded as related to 
bevacizumab was reported (hypertension, one patient). Four patients ( 8%) had cardiac failure. Survival 
rates at three years w ere encouraging, with 68% disease -free survival (DFS) and 90% overall survival 
(OS)9.  Furthermore, a po oled analysis of the BEVERLY -1 and BEVERLY -2 trials looking at the predictive 
and prognostic role of circulating tumor cells (CTCs) showed that the detection rate of CTCs was 39% with 
independent prognostic value for survival39.  After neoadjuvant therapy, the combination of pCR with no 
CTC detection at baseline yielded a subgroup of patients with IBC with improved prognosis (3 -year OS of 
94%).  Further larger and randomized studies evaluating the potential benefit of antiangiogenic therapy in 
this setting, as well as the role of CTCs as part of IBC stratification, are needed.  
 
A recently published phase II trial studied the clinical efficacy of neoadjuvant treatment with weekly 
carboplatin and paclitaxel plus oral metronomic cyclophosphamide in association with bevacizumab for 
patients with primary or recurrent IBC who were candidates for locoregional treatment40. Patients with 
HER2 -positive  IBC tumors received trastuzumab. Patients with HR -positive disease received concomitant 
endocrine therapy.  Oral metronomic capecitabine and cyclophosphamide was continued for 6 months after 
surgery in those patients with a response.  Thirty -four patients with IBC were included and t reatment was 
well tolerated and safe.  The overall response rate (ORR) was 88%, and the pCR rate was 29%, with the 
most significant effect of neoadjuvant the rapy observed in patients  with HER2 -positive cancer. The 
achievement of pCR was associ ated with longer DFS and OS.  
S17-[ADDRESS_730894] cancer was assessed in the randomized phase II GeparSixto 
trial ([STUDY_ID_REMOVED])41.  Patients were treated for 18 weeks with paclitaxel and non -pegylated liposomal 
doxorubicin. Those with TNBC received simultaneous bevacizumab.  Patients with HER2 -positive disease 
received simultaneous trastuzumab and lapatinib.  Patients were randomly assigned at the same to either 
carboplatin (AUC 1.5 [2.[ADDRESS_730895] 329 patients] once a wee k) or no carboplatin.  A total of 2 96 patients 
receive d carboplatin a nd another 296 patients did not receive carboplatin.  A total of 129 patients (95% CI, 
43.7; 38.1 -49.4) in the carboplatin group achieved a pCR , compared with 108 patients (95% CI, 36.9; 31.3-
42.4) without carboplatin (odds ra tio 1.33, 95% CI, 0.96 -1.85; p=0. 107).  For the patients with TNBC, 84 
(53.2%, 54.4 -60.9) of 158 patients achieved a pCR with ca rboplatin, compared with 58 (36.9%, 29.4 –44.5) 
of 157 without carboplatin (p=0. 005).  Howe ver, responses were not increased in patients with HER2 -
positive breast cancer.  Toxicities were significantly more common in the carboplatin group than in the no n 
carboplatin group including  grade 3 or 4 neutropenia, anemia, thrombocytopenia, and diarrhea .  Carboplatin 
was also more often associate d with dose discontinuations (141 [48%] with carboplatin and 114 [39%] 
without carboplatin; p=0.031).   
 
The C ALGB [ZIP_CODE] (Alliance) trial was a 2x2 factorial, open -label, randomized phase II trial that evaluated 
the impact of adding carboplatin and/or bevacizumab to ne oadjuvant paclitaxel followed by [CONTACT_556474]42.  Patients (n=443) with stage II to III TNBC received paclitaxel once per week 
for 12 weeks followed by [CONTACT_556475] 2 weeks for four cycles, and were 
randomly assigned to concurrent carboplatin (AUC 6) once every 3 weeks for four cycles and/or 
bevacizumab 10 mg/kg once every 2 weeks for nine cycles.   Results showed that patients assigned to 
either carboplatin or bevacizumab were less l ikely to complete weekly paclitaxel and doxorubicin plus 
cyclophosphamide without dose modification, skipped doses, or early discontinuation due to toxicity.  Grade 
3 or 4 neutropenia and thrombocytopenia were more common with carboplatin, and hypertension , infection, 
thromboembolic events, bleeding, and postoperative complications were more common with bevaci zumab. 
The addition of either carboplatin (60% v 44%; p=0.0018) or bevacizumab (59% v 48%; p=0.0089) 
significantly increased pCR in the breast, wherea s only carboplatin (54% v 41%; p=0.0029) significantly 
increased pCR in the breast/a xilla. More -than-additive interactions between the two agents could not be 
demonstrated.  
Of note, these trials did not show specific results for patients with IBC (GeparSi xto) or excluded IBC patients 
(CALGB [ZIP_CODE]).  Per international consensus on the clinical management of IBC from the Morgan Welch 
Inflammatory Breast Cancer Research Program 10th Anniversary Conference held at MDACC in 2017, 
although neoadjuvant carboplati n has been shown to increase pCR rates in TNBC, there is still not enough 
evidence supporting long term clinical efficacy at this time to recommend routine use in IBC6.   
1.3.6 Neoadjuvant  Therapy  with Anti -PD-1/PD -L1 A ntibodies in TNBC  
No neoadjuvant chemoimmunotherapy trial has been repo rted for IBC patients, however trials in TNBC are 
being conducted and early result s have shown promise.  The recently reported phase 2 randomized, 
multicenter I -SPY2  study (an adaptive trial platform to test novel agents) achieved an increase in pCR in 
patients who had locally advanced (stage  II/III) TNBC or HR -positive/HER2 -negative br east cancer when 
pembrolizumab was  added to the taxane seg ment of the standard neoadjuvant regimen, followed by 
[CONTACT_556476] ([STUDY_ID_REMOVED])43.  In total, 249 patients were randomized, of whom 
69 were to receive pe mbrolizumab in combination with paclitaxel, 180 were to receive paclitaxel alone in 
the control arm, and all patients then continued to receive neoadjuvant doxorubicin and cyclophosphamide. 
The findings indicated that the estimated pCR rate (negative patho logic post -treatment tumor 
classification/tumor in situ and negative pathologic post -treatment lymph node status [ypT0/Tis ypN0]) was 
significantly higher with the addition of pembrolizumab in patients who had TNBC (60% vs 20%, 
respectively) and in those w ho had HR -positive/HER2 -negative breast cancer (34% vs 13%) compared with 
S17-[ADDRESS_730896] th erapy, and the predictive prob ability of success in a phase 3 trial was 99%. No additive toxicities 
were observed except for an excess of adrenal insufficiency in the pemb rolizumab arm, which appeared to 
be greater than that  reported from chemoimmunother apy trials conducted in other cancer types. This finding 
is significant, because man agement requires long -term ste roid replacement for patien ts who are treated in 
the cura tive setting.  
 
Preliminary results from additional randomized neoadjuvant trials in TNBC combining standard cytotoxic 
regimens with immunotherapy also recently were reported. The phase 1b KEYNOTE -173 study evaluated 
pembrolizumab plus chemotherapy as neoadjuvant therapy for locally advanced  TNBC in 2 cohorts 
(NCT02 622074)44. Preliminary data were reported from 10 patients in cohort A ( single -dose 
pembrolizumab, fol lowed by 4 cycles of pembrolizumab every 3 weeks in combination with weekly nab -
paclitaxel, followed by 4 cycles of pembrolizuma b in combination with doxorubi cin 60 mg/ m2 and 
cyclophosphamide 600 mg/m2 every 3 weeks) and 10 patients in cohort B (the same treatme nt as in cohort 
A plus carboplatin at an area under curve (AUC) of 6 every 3 weeks was adde d to pembrolizumab and nab -
paclitaxel). The ypT0/Tis yp N0 pCR rate (no invasive resid ual disease in the breast and lymph nodes) was 
60% (90% CI, 30% -85%) in cohort A  and 90% (90% CI, 61% - 100%) in cohort B.  
 
In the randomized  phase 2 GeparNuevo study, dur valumab, a monoclonal antibody that binds to PD -L1, 
was added to an anthracycline -containing and taxane - containing neoadjuvant regimen for patients with 
TNBC (NCT02 685059)45.  The patients received durvalumab or placebo monotherapy for the first 2 weeks 
(window phase), followed by [CONTACT_556477] -paclitaxel weekly for [ADDRESS_730897] AEs included chemotherapy -related toxicities.  
In the recently reported phase 2  portion , a total of 174 patients were enrolled and all had comple ted 
treatment46.  Median age wa s 49.5 years [range 23.0 -76.0], and 44.5% of patients had cT1, 49.7% cT2, 
3.5% cT3, and 2.3% cT4  tumors. Eighty -three percent of the tumors were grade 3. Approximately 31% 
were cN -positive tumors.  Overall, the addition of durvalumab increased the pCR from 44.2 to 53.4%, 
although this was not statistically significant (OR 1.53).  As per subgroup anal ysis, the patients who started 
with durvalumab were found to have the greatest benefit with pCR of 61%. Additionally, patients with stage 
IIA or higher tumors and those who were 40 years of age or younger achieved a pCR rate of greater than 
60%.  A total o f 86 serious adverse events (SAEs)  and [ADDRESS_730898] (irAE SI) 
were reported; 34.5% of pts had at least one SAE and 27.6% had at least on e irAESI.  The irAESI were 
related to endocrine disorders of the thyroid gland.  In addition,  the safety of administering durvalumab 
concomitant with sequ ential taxane and anthracycline neoadjuvant chemotherapy was studied in a phase 
1/2 single -arm trial of stage I through III TNBC ([STUDY_ID_REMOVED]). Patients received durvalumab in 
combination with we ekly nab -paclitaxel, followed by [CONTACT_2715] -dens e doxorubicin and cyclophosphamide with 
durvalumab. The phase [ADDRESS_730899] neoadjuvant chemotherapy, toxicity has been observed and may be worse 
with t he combination with anthracycline .  Therefore at this time, only patients with poor prognosis —such as 
those with IBC —should be considered for these types of clinical studies, and concurrent th erapy with 
immunotherapy should b e given during  the non -anthracycline containing segment.  
 
1.3.7  Treatment wit h Anti -PD-1/PD -L1 A ntibodies in HER2 -positive Advanced Breast 
Cancer   
 
The phase Ib/II PANACEA trial (BIG 4 -13/IBCSG 45 -13) ([STUDY_ID_REMOVED])  evaluated the combination of 
pembrolizumab and trastuzumab in [ADDRESS_730900] cancer who had 
progressed on a prior trastuzumab -based therapy48. Tumors were assessed centrally for HER2 -positivity 
and programmed cell death ligand 1 (PD -L1) status, and for quantity of tumor -infiltrating lymphocytes (TILs).  
The phase Ib portion was a dose -escalation study of pembrolizumab, an anti -PD-[ADDRESS_730901] dose of trastuzumab. No dose -limiting toxicities were observed.  In the phase II portion, 
40 patients and 12 patients were enrolled to the PD -L1–positive and PD -L1–negative cohorts, respectively. 
Patients received [ADDRESS_730902] dose of 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  12 trastuzumab for 24 months or until  disease progression.  In the PD -L1–positive intent -to-treat population, 
the trial met its primary endpoint with an objective response rate of 15 % and disease control rate of 25%. 
In a subgroup of PD -L1–positive patients with 5% or more TILs present in the metastatic lesion, the 
objective response rate was 39% and the  disease control rate was 47 %.  No responses were observed in 
the PD -L1–negative c ohort.   Pembrolizumab with trastuzumab was well tolerated, with grade [ADDRESS_730903] commonly reported adverse event (21%). The most common immune -related adverse events 
reported were hyper - and hypo -thyroidism (grade 1 –2 at 6.7%) and pneumonitis (grade 3 -4 at 3.4%).  
 
1.3.[ADDRESS_730904] ID No.  
Randomized, phase 
II open label  
 
PELICAN: 
Immunotherapy in 
combination with 
chemotherapy in 
HER2 -negative IBC  
 FEC (if HR -positive IBC)
  
weekly paclitaxel  
 
dose -dense EC (if HR -
negative IBC) 
  weekly 
paclitaxel  
 
Experimental arm will 
receive pembrolizumab q 3 
weeks  during neoadjuvant 
chemoth erapy 
 HER2 -
negative IBC  81/ongoing  pCR 
(ypT0/is, 
ypN0 ) [STUDY_ID_REMOVED]  
 
Single arm, phase II 
open label  
Panitumumab, nab -
paclitaxel and 
carboplatin for 
HER2 -negative IBC  PNC (panitumumab + nab -
paclitaxel + c arboplatin ) + 
FEC (5-fluorouracil, 
epi[INVESTIGATOR_14962], and 
cyclophosphamide ) HER2 -
negative IBC  40/completed  pCR  
(ypT0, 
ypN0 ) [STUDY_ID_REMOVED]  
 
Single arm, p hase II 
open label  
Eribulin followed by 
[CONTACT_556478]2 -
negative  IBC 
 Eribulin 
  AC HER2 -
negative IBC  25/ongoing  pCR (will 
be reported 
as residual 
cancer 
burden 
[RCB])  [STUDY_ID_REMOVED]  
 
Randomized, phase 
II open label  
Ruxolitinib 
(INCB018424) with 
preoperative 
chemotherapy for 
triple negative IBC  Paclitaxel +/ - Ruxolitinib 
  
AC HR-/HER2 - 
IBC  64/ongoing  Assess 
JAK 
inhibition 
with 
Ruxolitinib 
on pStat3+ 
expressio n 
 [STUDY_ID_REMOVED]  
 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  13 Randomized, phase 
II open label  
Carboplatin/  
paclitaxel versus 
panitumuma b/ 
carboplatin/  
paclitaxel f ollowed  
by [CONTACT_511787] -
containing r egim en 
for newly diagnosed 
primary triple -
negative IBC  
 Carboplatin/Paclitaxel  
AC versus 
Panitumumab/C arboplatin/
Paclitaxel 
  AC HR-/HER2 - 
IBC  72/ongoing  pCR [STUDY_ID_REMOVED]  
 
Single arm, phase II 
open label  
 
Paclitaxel combined 
with trastuzumab 
and p ertuzumab as 
pre-operative 
therap y for IBC  
 Paclitaxel +Trastuzumab 
+Pertuzumab  
 
Mastectomy 
   
Option 1: AC 
  
Trastuzumab +P ertuzumab 
to complete one year of 
therapy  
Option 2: Trastuzumab 
+Pertuzumab to complete 
one year of therapy  HER2+ IBC  23/completed  pCR [STUDY_ID_REMOVED]  
 
 
1.4 Dose Rationale  and Schedule  
 
The treatment to be used in this trial is outlined below and in Table 2/3 and Table 4/5.  
 
Cohort 1: TNBC or HR-positive /HER2-negative  
 
1. Cycle 1 -4, 21 day cycle  
• Nivolumab 360 mg IV on Day 1 x 4 cycles and Paclitaxel 80 mg/m2 IV on Day 1, 8, and 15 x 4 
cycles, followed by  
 
2.  Cycle 5 -8, 14 day cycle  
• Doxorubicin 60 mg/m2 IV on Day 1 x 4 cycles and Cyclophosphamide 600 mg/m2 IV on Day 1 x 4 
cycles  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  14 Table 2  
 
Drug  Dose/  
Potency  Dose Frequency  Route of 
Administration  Use 
Nivolumab  
 360 mg  Day 1 of every 21 day cycle 
(Cycle 1 -4) Intravenous (IV)  Experimental  
Paclitaxel  80 mg/m2 Day of 1, 8, 15 of every 21 
day cycle (Cycle 1 -4) IV Standard  
Doxorubicin  60 mg/m2 Day of 1 of every 14 day 
cycle (Cycle 5 -8) IV Standard  
Cyclophosphamide  600 mg/m2  Day of 1 of every 14 day 
cycle (Cycle 5 -8) IV Standard  
 
Table 3  
 
 Cycle 1 -4  Cycle 5 -8  
Nivolumab  X  
Paclitaxel  X  
Doxorubicin   X 
Cyclophosphamide   X 
 
Cohort 2:  HR-positive/HR -negative and HER2 -positive :  
 
1. Cycle 1 -4, 21 day cycle  
• Nivolumab 360 mg IV on Day 1 x 4 cycles, + Docetaxel 75 mg/m2 IV on Day 1 x 4 cycles or 
Paclitaxel 80 mg/m2IV on Day 1, 8, and 15 x 4 cycles, + Trastuzumab * 8 mg/kg IV on Day 1 of 
Cycle 1 and then 6 mg/kg IV on Day 1 of Cycle 2 -4, + Pertuzumab 840 mg IV on Day 1 of Cycle 1 
and then 420 mg IV on Day 1 of Cycle 2 -4, followed by  
 
2. Cycle 5 -8, 14 d ay cycle  
• Doxorubicin 60 mg/m2 IV on Day 1 x 4 cycles and Cyclophosphamide 600 mg/m2 IV on Day 1 x 4 
cycles  
 
*Trastuzumab biosimilar is allowed  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  15 Table 4  
 
Drug  Dose/  
Potency  Dose Frequency  Route of 
Administration  Use 
Nivolumab  
 360 mg  Day 1 of every 21  day cycle  
(Cycle 1 -4) Intravenous  (IV) Experimental  
Docetaxel  
(or Paclitaxel)  75 mg/m2  
(80 mg/m2) Day 1 of every 21 day cycle  
(Day 1, 8, 15 of every 21 day 
cycle)  
(Cycle 1 -4) IV Standard  
Trastuzumab  
(biosimilar is 
allowed)  8 mg/kg IV on 
Day 1 of Cycle 
1 and then 6 
mg/kg IV on 
Day 1 of Cycle 
2-4  Day 1 of Cycle 1 and then 
Day 1 of subsequent cycles 
(2-4) (Cycle 1 -4) 
Each cycle is [ADDRESS_730905]  
Pertuzumab  840 mg on Day 
1 of Cycle 1 
and then 420 
mg IV on Day 1 
of Cycle 2 -4 Day 1 of Cycle 1 and then 
Day 1 of subsequent cycles 
(2-4) (Cycle 1 -4) 
Each cycle is [ADDRESS_730906]  
Doxorubicin  60 mg/m2 Day 1 of every 14 day cycle 
(Cycle 5 -8) IV Standard  
 
Cyclophosphamide  600 mg/m2  Day 1 of every 14 day cycle 
(Cycle 5 -8) IV Standard  
 
Table 5  
 
 Cycle 1 -4  Cycle  5-8  
Nivolumab  X  
Docetaxel (or Paclitaxel)  X  
Trastuzumab  X  
Pertuzumab  X  
Doxorubicin   X 
Cyclophosphamide   X 
 
 
Postoperative Therapy:  
 
• After mastectomy and axillary lymph node dissection , radiation therapy is recommended as per 
institutional guidelines.   
• Patients with HR -positive tumors should receive a minimum  of 5 years of adjuvant endocrine 
therapy.  Choice of endocrine therapy is at the discretion of the investigator.   
• For HER2 -positive tumors, patients with residual disease after neoadjuvant therapy may receive 
ado-trastuzumab emtansine (T -DM1) in the adjuv ant setting for 14 cycles49.  Another option is to 
continue tra stuzumab with or without pertuzumab to complete one year  of HER2 -directed therapy35.  
For pati ents with pathologic complete response (no residual disease), adjuvant trastuzumab can 
be con tinued with or without pertuzumab to complete one year of HER2 -directed therapy.   
Treatment regimen is at the discretion of the investigator.    
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  16 • Use of adjuvant capecitabine for 6 -8 cycles (permissible after surgery) for patients with TNBC with 
residual disease is at the discretion of the investigator50.   
 
1.4.1 Rationale for N ivolumab  Dose and S chedule   
 
The FDA approved dose of nivolumab is 240 mg IV (flat dose) every 2 weeks or 480 mg IV (flat dose) every 
4 weeks in malignancies such colorectal cancer ( microsatellite instability -high or mismatch repair deficient ), 
recurrent or metastatic squamous cell head and neck cancer, hepatocellular carcinoma, melanoma, 
metastatic NSCLC, metastatic renal cell cancer, or urothelial carcinoma.  This is equal to [ADDRESS_730907] been per formed to support use of nivolumab 360 mg every 
three weeks.   The phase III CheckMate -227 trial evaluated the combination of  nivolumab and ipi[INVESTIGATOR_556434] -naïve patients with NSCLC with high tumor mutation burden (TMB)51.  
Patients with a PD -L1 expression level of less than 1% were randomly assigned (in a 1:1:1 ratio), with 
stratification according to tumor histologic type, to receive nivolumab (3 mg per kilogram every 2 weeks) 
plus ipi[INVESTIGATOR_125]  (1 mg per kilogram every 6 weeks), platinum doublet chemotherapy based on tumor 
histologic type every 3 weeks for up to four cycles, or nivolumab  (360 mg) plus platinum doublet 
chemotherapy based on tumor histologic type every [ADDRESS_730908] 
taxane chemotherapy with paclitaxel and docetaxel or with HER2 -targeted therapy with trastuzumab and 
pertuzumab.  It will not be given at the same time as the anthracycline -based therapy (doxorubicin and 
cyclophosphamide) due to a potential increased risk of cardiotoxicity. Of note, c ombination therapi[INVESTIGATOR_556435] -
1/PD -L1 checkpoint inhibitors and taxane chemotherapy have no t identified excessive toxicity.  A phase Ib 
study evaluated atezolizumab (anti -PD-1 antibody) plus nab -paclitaxel in patients with metastatic TNBC, 
and the combination was well -tolerated without additive toxicity53.  In the randomized IMpassion 130 trial 
(n=902) with nab -paclitaxel and atezoli zumab or placebo, grade ≥3 adverse events occurred in 49% of 
patients receiving atezolizumab and 42% of patients receiving placebo, with grade 3 or 4 neuropathy 
occurring more frequently among those re ceiving atezolizumab (5.5%  versus 2.8% )22.  A phase Ib/II trial 
studied  pembrolizumab (anti -PD-1 antibody) and HER2 -directed agent, trastuzumab, i n advanced HER2 -
positive breast cancer , and the combination was also found to be safe without excess cardiac toxicity48.   
1.4.[ADDRESS_730909] Cancer Trialists' Collaborative Group (EBCTCG) 
demonstrated benefit for anthracycline -based regimens over cyclophosphamide, methotrexate, plus 
fluorouracil (CMF)54.  In addition, adding taxanes to anthracyclines furt her improved outcomes in the 
adjuvant setting.  Further rationale for the use of anthracyclines and taxanes in the preoperative setting 
comes from clinical trials of neoadjuvant treatment . In this  setting, multiple studies have shown that addition 
of a tax ane to an anthracycline -based regimen  is associated with increased response rates55-58.   
 
The Neo -tAnGo  neoa djuvant trial assessed the sequencing of chemotherapy by [CONTACT_556479][INVESTIGATOR_556436] (with or without gemcitabine)59. A total of 831 patients were randomized;  
207 received epi[INVESTIGATOR_556437]; 208 were given paclitaxel then epi[INVESTIGATOR_556438]; 208 had epi[INVESTIGATOR_556439]; 
and 208 received paclitaxel and gemcitabine then epi[INVESTIGATOR_397090]. 828 patients were 
eligible for analysis. Median follow -up was 47 months, and 207 (25%) patients had inflammatory or locally 
advanced disease, 276 (33%) patients had estrogen receptor (ER) -negative disease, and 191 (27%) 
patients had HER2 -positive disease. Addition of gemcitabine did not increase pCR: 70 (17%, 95% CI 14 –
21) of 404 patients in the epi[INVESTIGATOR_556440] 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  17 with 71 (17%, 14 –21) of 408 patients who received addit ional gemcitabine (p=0·98). Receipt of a taxane 
before the anthracycline was associated with improved pCR: 82 (20%, 95% CI 16 –24) of 406 patients who 
received paclitaxel with or without gemcitabine followed by [CONTACT_14198][INVESTIGATOR_556441] 59 (15%, 11 –18) of [ADDRESS_730910] (p= 
0.03).  Although addition of gemcitabine to paclitaxel and epi[INVESTIGATOR_556442], sequencing chemotherapy so tha t taxanes are rece ived before anthracyclines may 
improve pCR with  standard neoadjuvant  chemotherapy for breast cancer.   
 
In the current study, the taxane -based chemotherapy (paclitaxel or docetaxel) will be given prior to the 
anthracycline -based chemother apy (doxorubicin and cyclophosphamide).  S tandard dose and schedule of 
paclitaxel, docetaxal, doxorubicin, and cyclophosphamide will be used (Section 1.4) . 
 
HER2 -targeted therapy with t rastuzumab and pertuzumab  
 
For patients with HER2 -positive breast cancer that are candidates for preoperative systemic therapy, 
chemotherapy and trastuzumab -based therapy are  recommended. Chemotherapy and dual anti -HER2 
blockade associated with  trastuzumab plus pertuzumab have  shown  significant improvements in the pCR 
rate when compared with chemotherapy and one anti -HER2 agent in the preoperative setting. In the 
NeoS phere trial, the addition of pertuzumab to trastuzumab and docetaxel preoperatively led to a 
statistically significant  increase in pCR in the breast (16.8% increase; 95% CI, 3.5 –30.1; p= 0.0141)14.  In 
the TRYPHAENA trial, preoperative therapy with pertuz umab and trastuzumab given alone  with or without 
anthracycline -contain ing chemotherapy r egimens demonstrated  pCR rates in all treatment arms ranging 
from 57% to 66%33.  The mean change in LVEF w as similar in all treatment arms. The FDA granted 
accelerated approval i n 2013 for t he addition of pertuzumab to neo adjuvant chemotherapy and trastuzumab 
for patients with HER2 -positive locally advanced, inflammatory, or early -stage (either greater than 2 cm in 
diameter or node positive) breast cancer.  
 
In the current study, t he standard dose and schedule of trastuzumab and pertuzumab will be used (Section 
1.4).  Use of trastuzumab biosimilar is allowed.  
1.5 Research Risks & Benefits  
1.5.1  Risk of Study Drug  
 
Dose modifications for nivolumab  are described in 5.3.   While this is a greater than minimal risk study,  
combination therapi[INVESTIGATOR_556435] -1/PD -L1 checkpoint inhibitors  with taxane chemotherapy or HER2 -directed 
therapy with trastuzumab were found to be safe48,53.  The safety of the addition of nivolumab to standard 
chemotherapy  will be closely monitored in this study, as described in Sections 4.3.11 and 6.1 . 
1.5.2  Other Risks of Study Participation  
 
Additional risks to study participation are listed in the consent form and include breach of confidentiality, 
not deriving benefit from the study treatment, and procedures performed for research only (peripheral blood 
draws and tumor tissue biopsies for correlative studies). Privacy protection procedures are in place and 
good clinical practice gui delines are followed for the study to minimize risks associated with research 
procedures and participation.  
1.5.3  Potential B enefits  
 
It is not known if participation in the study will be beneficial for the patient, although it is anticipated that 
patients will derive clinical benefit from treatment with the combination of nivolumab and chemotherapy.  
 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  18 2 Study Objectives  and Hypotheses  
2.1 Study Objectives  
 
Primary Objective  
 
• To determine whether the addition of nivolumab to chemotherapy improves pathologic complete 
response (pCR) in the breast and post -therapy lymph nodes evaluated histologically in patients 
with inflammatory breast cancer  (IBC) .  This is defined as no histologic evidence of invasive tumor 
cells in the surgical breast specimen, axillary node s, or sentinel node identified after neoadjuvant 
chemotherapy (ypT0/Tis ypN0).  
 
Secondary Objectives  
 
• To evaluate the safety and tolerability of the combination of nivolumab with  neoadjuvant 
chemotherapy  in IBC.  
• To evaluate  the invasive recurrence -free int erval (IRFI) [time  frame:  up to 24 months after study 
entry]. This is assessed as the time from study entry until diagnosis of the first invasive local, 
regional, or distant breast cancer recurrence during the 24 months after study entry.  
 
Correlative Objectives  
 
• To evaluate  PD-L1 expression on tumor and tumor -infiltrating immune cells as a predictor for pCR 
following treatment with neoadjuvant nivolumab and chemotherapy . 
• To assess the frequency of mutational and neoantigen load and to explore mutational and 
neoantigen load as predictive markers of response.  
• To assess changes in expression levels of biomarkers or biomarker panels before, during, and 
after treatment.  
 
2.2    Hypotheses  
 
Primary Hypothesis  
 
• For HER2 -negative cohort  (including TNBC or HR -positive) , the combination of nivolumab  with 
neoadjuvant chemotherapy will result in a pCR rate greater than 10% in IBC.   
• For HER2 -positive cohort  (independent of HR status) , the combination of nivolumab  with 
neoadjuvant chemotherap y will result in a pCR rate greater than 25% in IBC.   
 
Secondary Hypotheses  
 
• Treatment with the combination of nivolumab and chemotherapy  is safe and well tolerated.  
• The combination of nivolumab and chemotherapy  will be active (as determined by [CONTACT_556480] ) 
in patients with IBC. 
• Subjects with tumoral PD -L1 expression will demonstrate improved pCR rate, clinical response, 
and IRFI compared to subjects without PD -L1 expression.  
 
Exploratory Hypotheses  
 
• Patients wi th tumors containing higher  expression of PD -L1 and TILs will have higher  pCR rate and 
IRFI compared with patients with tumors with little or no expression.  
• Predictive biomarkers in tumor tissue and peripheral blood can be detected.  
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  19 • Changes in biomarkers during therapy are predictive of clinical response or resistance in patients 
treated with the combination of nivolumab and chemotherapy.  
 
3 Study Design  
3.1 General Design  
 
This is an open l abel, multicenter, p hase II clinical trial designed to study the efficacy and safety of 
nivolumab in combination with neoadjuvant chemotherapy for patients with IBC  (n=52).  
 
 Cohort 1:  HER2 -negative, including TNBC or HR -positive (26 patients)  
 Cohort 2:  HER2 -positive, indepen dent of HR status (26 patients)  
 
Expression of tumoral PD -L1 is not required for study entry.  
 
There will be an interim safety analysis in Cohort [ADDRESS_730911]-mastectomy radiotherapy  (per institutional guidelines)  is warranted and targets 
shou ld include the chest wall and supraclavicular, infraclavicular, and internal mammary chain nodes.   
Patients with HR -positive tumors should receive a minimum  of 5 years of adjuvant hormonal therapy.  
Choice of hormonal therapy is at the discretion of the in vestigator.  For HER2 -positive tumors, patients with 
residual disease after neoadjuvant therapy may receive ado -trastuzumab emtansine (T -DM1) in the 
adjuvant setting for 14 cycles49.  Another option is to continue trastuzumab with or without pertuzumab to 
complete one year  of HER2 -directed therapy35.  For patients with pathologic complete response (no residual 
disease) , adjuvant trastuzumab can be continued with or without pertuzumab to complete one year of 
HER2 -directed therapy. Treatment regimen is the discretion of the investigator. T he use of adjuvant 
capecitabine for 6 -8 cycles for patients (permissible after surgery ) with TNBC with residual disease is at the 
discretion of the investigator50.   
 
 
 
 
 
 
 
 
 
 
 
 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  20 Study Schema  (n=52)  
 
 
 
3.2 Primary Study Endpoint  
 
Pathologic complete response (pCR), which is defined as no histologic evidence of invasive tumor cells in 
the surgical breast specimen, axillary nodes, or sentinel node (s) identified after neoadjuvant chemotherapy 
(ypT0/Tis ypN0).  
3.3 Secondary Study Endpoints  
 
a) Patient tolerability and safety with the combination  will be assessed using NCI Common Terminology 
Criteria for Adverse Events  (CTCAE) version 5.  
 
b) To estimate the invasive recurrence -free interval (IRFI) [time  frame:  up to 24 months after study entry]. 
This is assessed as the time from study entry until diagnosis of the first invasive local, regional, or distant 
breast cancer recurrence during the 24 months after study entry  (would exclude contralat eral new 
primaries) . 
3.[ADDRESS_730912] clinical response to nivolumab will be investigated i n tumor 
specimens  and peripheral blood.  These will provide important information regarding biological effe cts of 
this combination therapy in IBC, and changes in patterns based on response  to or resistance to therapy.  

S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  21  
• Baseline tumoral expression of PD -L1 and expression of PD -L1 during and  following treatment with 
nivolumab and chemotherapy as a predictor for pCR and IRFI will be evaluated. Composition of 
immune response will be investigated, including T cell repertoire, macrophage response, select 
cytokine, transcription factor, and protei n kinase responses (e.g. JAK2, mTORC1, IL8, STAT3).  
• The frequency of mutational and neoantigen load will be studied as predictive markers of response.  
• Changes in expression levels of biomarkers or biomarker panels before, during , and afte r treatment 
will b e evaluated.  
 
[ADDRESS_730913] meet ALL of the following inclusion criteria to be eligible for study entry:  
 
• Histological diagnosis of invasive adenocarcinoma of the breast and a clinical diagnosis of IBC 
based on presence of inflammatory changes in the involved breast, including erythema and edema 
(peau d'orange), with or without an underlying palpable mass involving a third or more  of the skin 
of the breast ( T4d according to American Joint Committe e on Cancer (AJCC) breast cancer 
staging, 8th ed.). Pathological evidence of dermal lymphatic invasion should be noted but is not 
required for diagnosis of IBC. 
• In case of bilateral cancer, the investigator should decide prospectively which side will be evaluated 
for the primary  endpoint.  
• Local CLIA -certif ied laboratory testing  on the tumor tissue specimen for ER, PR, and HER2 must 
be performed:  
o Hormone Receptor (HR) -positive : defined as estrogen receptor (ER) and/or progesterone  
             receptor (PR) ≥ 1% per ASCO -CAP guidelines60 
o HER2 -positive : IHC 3+ or 2+ with HER2/CEP17 ratio >2.0 or average HER2 copy number 
>6.0 signals/cel l per ASCO -CAP guidelines61 
o TNBC : defined as ER/PR<1% and HER2 -negative  per ASCO -CAP guidelines60  
• Age > 18 years , individuals of all races and ethnic groups are eligible  
• Eastern Cooperative Group (ECOG) performance status of 0 or 1 (see Appendix 2 ) 
• LVEF  assessment performed by [CONTACT_556481].  Results must be a t or a bove the normal limit of  the institution and/or ≥50 %.  
• All patients with disease that is deemed by [CONTACT_70440] I nvestigator as safely accessible to biopsy 
are required to undergo research biopsies as outlined in this protocol  
• Ability to understand and willingness to sign a written informed consent document or if appropriate, 
have an acceptable surrogate capable of g iving consent on the subject’s behalf  
• Adequate hematologic and end -organ function, as evidenced by [CONTACT_556482] [ADDRESS_730914] study treatment (Cycle 1, Day 1):  
 
Table 6:  Adequate Organ Function Labora tory Values  
System  Laboratory Value  
Hematologic   
Absolute neutrophil count (ANC)  ≥ 1,500/mcL  
Platelets  ≥ 100,000/mcL (without transfusion within 1 week 
prior to Cycle 1, Day 1)  
Hemoglobin  ≥ 9 g/dL or ≥  5.6 mmol/L (without transfusion or EPO 
dependency within 1 week prior to Cycle 1, Day 1)  
Renal   
Serum creatinine OR ≤ 1.5 X upper limit of normal (ULN)  
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  22 Measured or calculated creatinine 
clearancea (can also be used in 
place of creatinine or CrCl)  OR 
≥ 60 mL/min for s ubject with creatinine levels > 1.[ADDRESS_730915]  
Hepatic   
Serum total bilirubin  ≤ 1.[ADDRESS_730916] bilirubin ≤ ULN for subjects with total bilirubin 
levels > 1.[ADDRESS_730917] and ALT  ≤ 2.5 X UL N  
Albumin  > 2.5 mg/dL  
Coagulation  
International Normalized Ratio 
(INR) or Prothrombin Time (PT)  
 
Activated Partial Thromboplastin 
Time (aPTT)  ≤ 1.[ADDRESS_730918] is receiving 
anticoagulant therapy as long as PT or PTT is within 
therapeutic range of intended use of anticoagulants  
 
≤ 1.[ADDRESS_730919]  
 
• For women of childbearing potential  (pre-menopausal women and women less than 12 months 
after the onset of menopause ): must have a pregnancy test every [ADDRESS_730920] (minimum sensitivity 25 IU/L or equivalent units of HCG) 
within 24 hours prior to the start of nivolumab . 
• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual 
intercourse) or use adequate contraceptive measures  (barrier methods, intrauterine contraceptive 
devices, sterilization) du ring study treatment  and for a total of [ADDRESS_730921] -treatment completion .  
A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached 
a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cau se other 
than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus) . 
• For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use 
contraceptive measures, and agreement to refrain from donating sperm  
4.2 Exclusion Criteria  
 
Patients who meet any ONE of the following criteria will be excluded from study entry:  
 
• Definitive clinical or radiologic evidence of distant metastases  
• Has a known additional malignancy that progressed within the last five years  
• Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included 
in the treatment regimens  
• Patients known to be HIV positive  
• Neuropathy  ≥ Grade 2, per the NCI CTCAE v 5.0 
• History of allogeneic stem cell or solid o rgan transplantation  
• Has active clinically significant autoimmune disease where in the opi[INVESTIGATOR_556443]  
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), or 
evidence of active pneumonitis  
• Patients with  clinically active tuberculosis  
• Pregnancy or lactation at the time of enrollment  
• Prior treatment with CD137 agonists or immune checkpoint−blockade therapi[INVESTIGATOR_014], including anti -
CD40, anti−CTLA -4, anti−PD -1, and an ti−PD-L1 therapeutic antibodies  
• Treatment with systemic immunosuppressive medications (including but not limited to interferons, 
IL-2) within 28 days or 5 half -lives of the drug, whichever is longer, prior to study entry  
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  23 • Treatment with systemic immunosuppres sive medications (including but not limited to prednisone, 
cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti−tumor necrosis [anti -TNF] 
factor agents) within 2 weeks prior to randomization or anticipation of need for systemic 
immunosuppres sive medications during the study.  
• Cardiopulmonary dysfunction as defined by:  
o Inadequate LVEF at baseline, < 50% by [CONTACT_556483]  
o History of symptomatic  congestive heart failure (CHF): Grade ≥ 3 per NCI CTCAE 
version 5.0 or Class ≥  II per [LOCATION_001] Health Association  
o History of a decrease in LVEF to < 40% or symptomatic CHF  
o Myocardial infarction or unstable angina within [ADDRESS_730922] due to complications of malignancy, or other disease requiring 
continuous oxygen therapy  
o Corrected QT interval (QTc) > 450 msec on screening EKG  
• Clinically significant history of liver disease, including cirrhosis, autoimmune hepatic disorders, HIV 
infection, or active Hepatitis B or Hepatitis C  
o Active infect ion requiring treatment with antiviral therapy or presenc e of positive test 
results for Hepatitis B (e.g. Hepatitis B surface antigen and/or total Hepatitis B core 
antibody) or HCV antibody.  
o HBV and HCV assessments are required at screening.  
o Patients who test positive for Hepatitis B core antibody are eligible if polymerase chain 
reaction (PCR) is negative for HBV  DNA  
o Patients who are positive for HCV serology are only eligible if testing for HCV RNA is  
negative  
• Subject is pregnant or nursing  
• Known documented or suspected hypersensitivity to the components of the study drugs(s)  
 
4.[ADDRESS_730923] Recruitment/ Screening  and Clinical Procedures/Assessments  
 
Target enrollment for this study is [ADDRESS_730924] the patient’s 
privacy.   
 
Prior to study entry, a patient’s eligibility must be approved in writing (email is allowed) by [CONTACT_556484].  
 
The P rincipal  Investigator will:  
 
1. Obtain signed and dated informed consent from the potential subject before any study specific 
procedures are performed.  
 
2.  Determine patient eligibility (See Section 4.1 and 4.2) . 
 
  3.  Submit registration to NYU Perlmutter Cancer Center CTO.  
 
               4.  Receive registration confirmation from NYU Perlmutter Cancer Center CTO, including unique     
       study identification number assigned to the patient that will be distributed to the study team      
       upon registration of the patient.  
 
S17-[ADDRESS_730925]’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally acceptable 
representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated signature [CONTACT_556528].  A copy of the signed and dated consent form should be given to the subject before 
participation  in the trial.  
 
The initial informed consent form, any subsequent revised written informed consent form and any written 
information provided to the subject must receive the NYU Institutional Review Board’s (IRB) 
approval/favorable opi[INVESTIGATOR_19349] .  The subject or his/her legally acceptable representative 
should be informed in a timely manner if new information becomes available that may be relevant to the 
subject’s willingness to continue participation in the trial.  The communication of this info rmation will be 
provided and documented via a revised consent form or addendum to the original consent form that 
captures the subject’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally acceptable representative’s dated 
signature.  
 
Specifics about a trial and th e trial population will be added to the consent form template at the protocol 
level.   
 
The informed consent will adhere to NYU IRB requirements, applicable laws and regulations , and Sponsor 
requirements.  
 
For non -English speaking patients, institutional translation services will be utilized.  All procedures for 
consenting non -English speaking patients will be in accordance with NYU Langone Health PCC CTO 
guidelines and policies.  
 
For patients who cannot read, a  witness, not related to the re search study , will be present. The consent will 
be read to the patient. The patient will also be allowed to ask an y questions s/he may have. The I nvestigator 
will ask the patient questions to ensure s/he  understands the study. If the I nvestigator determine s the 
subject understands the study, the patient will mark an X where his/her name [CONTACT_556529].  
 
4.3.[ADDRESS_730926]’s medical chart . 
4.3.3   Mul ti-Site Surveillance  
As the lead i nvestigator in a multi -site trial, the Overall Principal  Investigator [INVESTIGATOR_556444].  The PI [INVESTIGATOR_556445] f rom all of the participating sites within the overall trial’s quarterly Data and Safety Monitoring 
report s to the Data Safety and Monitoring Committee ( DSMC ) to include minutes fr om monthly PI 
[INVESTIGATOR_28666]. Each participating site will be responsible fo r submitting the results and recommendations 
from the DSMC’s quarterly  review to their IRB of record at the time of continuing review.   Additionally, the 
NYU Langone Health PCC Clinical Trial Office, Quality Assurance Unit will provide a remote extensive 
monitoring including real -time review of all eCRF’s to ensure completeness and compliance with the 
protocol (100% source documentation verification).  Additionally, a first subject audit is to be completed 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  25 with four weeks of enrollment.   
4.3.4   Patient In formed Consent at Additional Sites  
See Appendix 1 . 
 
4.3.5   Inclusion/Exclusion Criteria  
All inclusion and exclusion criteria will be reviewed by [CONTACT_556485].  
4.3.[ADDRESS_730927] prior medication (s) taken 
by [CONTACT_2690] [ADDRESS_730928] during the trial.  
All medications related to reportable serious adverse events (SAE) and events of clinical interest (ECI) 
should be recorded as defined in Section 8.2 . 
 
4.3.9  Disease Details  
The I nvestigator or qualified designee will obta in prior and current details regarding disease status  as per 
AJCC 8th edition .  
 
Clinical Procedures/Assessments  
4.3.10  Adverse Event (AE) Monitoring  
The I nvestigator or qualified designee will assess each subject to evaluate for potential new or worsening 
AEs as specified in the Study Schedule of Events (Section 6.1)  and more frequently if clinically indicated.  
Adverse experiences will be graded and record ed throughout the study and during the follow -up period 
according to NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Toxicities will be 
characterized in terms regarding seriousness, causality , toxicity grading, and action taken with  regard to 
trial treatment.   
4.3.11  Full Physical Exam  
The Investigator or qualified designee will perform a complete physical exam during the screening period.  
Clinically significant abnormal findings should be recorded as medical history.   
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  26 4.3.12  Directed Physical Exam  
At subsequent visits (or as clinically indicated), direc ted physical examinations can  be performed. Changes 
from baseline abnormalities should be recorded in the patient notes.  
4.3.13  Vital Signs  
The Investigator or qualified designee will take vital signs at screening, prior to the administration of each 
dose of trial treatment, and at treatment discontinuation as specified in the Study Schedule of Events 
(Section 6.1) .  Vital signs should include  temperature, pulse, respi[INVESTIGATOR_697], weight, height  (Screening 
only)  and blood pressure.   
4.3.14  Eastern Cooperative Oncology Group (ECOG) Performance S tatus  
The I nvestigator or qualified designee will assess ECOG performance status at screening, prior to the 
administration of each dose of trial treatment and discontinuation of tri al treatment as specified in Study 
Schedule of Events (Section 6.1) and Appendix 2 . 
4.3.15  Collection of Tumor Tissue Prior To Treatment  
Collection of formali n-fixed paraffin -embedded (FFPE) tumor tissue from diagnostic core biopsy within  60 
days  prior to enrollment  (Cycle 1 Day 1) is required. If available, a fresh biopsy sample is preferred.  Testing  
by a CLIA -certified local laboratory on the tumor tissue specimen for ER, PR, and HER2 must be performed .   
4.3.16   Tumor Imaging / Cardiac Imaging   
 
Initial imaging assessments must include bilateral mammogram and/or bilateral ultrasound.  Bilateral breast  
MRI is optional.  Imaging must also be performed at screening to rule out distant disease.  CT scans (with 
IV contrast and oral contrast unless contraindicated) of the chest, abdomen, and pelvis or Positron emission 
tomography (PET)/CT may be used.  If a CT scan for tumor assessment is performed as part of a PET/CT, 
the CT acquisition must be consistent with the standards for a full -contrast diagnostic CT scan.  MRI scans 
of the chest, abdomen, and pelvis may be used in patients for whom CT scans with cont rast are 
contraindicated (i.e., patients with contrast allergy or impaired renal clearance). A bone scan or PET scan 
should be performed to  evaluate for bone metastases if there is clinical suspi[INVESTIGATOR_556446].  
Imaging assessments should be  done within 60 days prior to enrollment  (Cycle 1 Day 1) . 
 
LVEF assessment by [CONTACT_6751] ( TTE) or by [CONTACT_556486] 60 days prior to enrollment  
(Cycle 1 Day 1) . 
 
4.3.17  Laboratory Procedures/Assessments  
Details regarding specific laboratory procedures/assessments to be performed in this trial are provided in 
the Study Schedule of Events (Section 6.1) . 
 
Laboratory tests for screening or entry into the study should be performed within 30 days  prior to enrol lment  
(Cycle 1 Day 1) .  For subsequent cycles a fter Cycle 1, pre -dose laboratory procedures can be conducted 
up to [ADDRESS_730929] be reviewed by [CONTACT_556487].  
 
4.3.18   Tumor Assessment during Study Treatment   
Clinical evaluation, with a bidimensional measurement of the tumor , will be performed every three weeks 
during Cycle 1 -4 and every two weeks during Cycle 5 -8. For subjects  with no palpable mass , changes in 
clinically evaluable skin criteria ( such as erythema, edema, peau d’orange) will be considered as respons e 
criteria.  Patients should also have re -evaluation of the primary tumor by [CONTACT_556488], 
S17-[ADDRESS_730930]  ultrasound, and/or breast MRI  after the end of Cycle 8 (prior to surgery). In the case of progressive 
disease, see Section 6.2 . 
4.3.19   Screening Period  
The screening phase is the interval between the signing of the Informed Consent Form (I CF) and the day 
the sub ject is enrolled in the study (Cycle 1 Day 1 ). Informed  consent must be obtained prior to performing 
any study -specific procedures. Assessments that are required to demonstrate eligibility may be performed 
over 1 or more days during this phase.  
 
Screening procedure  timeline :  
 
• Laboratory tests and EKG may be  performed within 30 days prior to enrollment.  
• Women of reproductive potential mu st have a negative urine or serum pregnancy test within [ADDRESS_730931] dose of study treatment . 
• Tumor  tissue biopsy may be obtained within 60 days prior to enrollment  
• Tumor imaging assessment may be done within 60 days prior to enrollment.  
• Echocardiogram or MUGA assessment may be done within [ADDRESS_730932] eligibility prior to 
enrollment /administration of study drug via investigator and CTO personnel . Tests with results that fail 
eligibility requirements may  be rep eated once during the screening phase, if the Investigator believes the 
results to be in error or not representative. Additionally, a subject who fails screening may repeat the 
screening process one time, if the Investigator believes there has been a chang e in eligibility status (e.g. 
following recovery from an infection).  
 
Additionally , the screening period will be utilized to determine the baseline assessments of clinical condition 
and disease status. Tumor assessments appropriate to the type of malignanc y will be performed and 
recorded in the case report form ( CRF). 
 
4.[ADDRESS_730933] sign and date an informed consent form before undergoing any study specific procedure 
unless a procedure is being performed as part of the patient’s standard of care.  Enrollment in the study 
requires that all inclusion and exclusion crit eria have been met.  Enrollment occurs upon confirmation of 
registration from the  NYU  PCC Clinical Trials Office.  The following materials must be submitted to the CTO 
for subject registration:  
 
1. Complete signed and dated informed consent form  
2. Complete sign ed and dated eligibility checklist  
3. All supporting documentation verifying each eligibility criterion has been met  
 
Registration will occur within [ADDRESS_730934] for any of the 
following reasons:  
 
• The subject or legal representative (such as a parent or legal guardian) withdraws consent  
• Disease progression or occurrence of a secondary malignancy which requires systemic therapy 
or radiotherapy for treatment.  
• Unacceptable adverse events as described in Section 5.3  
• Intercurrent illness that prevents further administration of treatment  
• Investigator’s decision t o withdraw the subject  
• The subject has a confirmed positive serum pregnancy test  
• Noncompliance with trial treatment or procedure requirements  
• The subject is lost to follow -up 
 
4.5.[ADDRESS_730935] may be withdrawn by [CONTACT_556489], the trial plan is violated, or for 
administrative and/or other safety reasons.  Specific details regarding discontinuation or withdrawal are 
provided in Section 4.5 . 
 
The End of Trea tment and Follow -up visit procedures are listed in the Study Schedule of Events ( Section 
6.1) and Section 6.[ADDRESS_730936] follow -up 
period.   
 
5 Study Drug  
5.1 Description  
 
Nivolumab, also referred to as BMS -936558 -01 or BMS -936558, is a soluble protein consisting  of 4 
polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. The  physical and 
chemical properties of nivolumab are: 
 
Molecular Weight :  146,221 daltons (143,619.17 daltons, protein portion)  
Appearance:    Clear to opalescent, colorless to pale yellow liquid, light (few) part iculates may   
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  29  be present  
Solution :    pH 5.5 to 6.5  
 
5.1.1  Pharmaceutical Properties and Formulation  
 
Nivolumab Injection, 100 mg/10 mL (10 mg/mL), is a clear to  opalescent, colorless to pale yellow liquid, 
which may contain light (few) particulates. The drug  product is a sterile, non -pyrogenic, single -use, isotonic 
aqueous solution formulated at 10 mg/mL  in sodium citrate, sodium chloride, mannitol, 
diethylenetriaminepentacetic acid (pentetic acid),  and polysorbate 80 (TweenTM 80), at pH 6.[ADDRESS_730937] Preparation  
 
Nivolumab injection is to be administered as an IV infusion thr ough a 0.2 -micron to 1.2 -micron pore size, 
low-protein binding (polyethersulfone membrane) in -line filter at the protocol -specified  doses and infusion 
times. It is not to be administered as an IV push or bolus injection. When the  dose is based on patient 
weight (i .e., mg/kg), nivolumab injection can be infused undiluted  (10 mg/mL) or diluted with 0.9% s odium 
chloride injection, USP or 5% dextrose injecti on, USP to protein concentrations as low as 0.35 mg/mL. 
When the dose is fixed (e .g., 240 mg, 360 mg, or  480 mg flat dose), nivolumab injection can be infused 
undiluted or diluted so as not to exceed a  total infusion volume of [ADDRESS_730938] be stored at 2oC to 8oC (36oF to 46oF) and protected from light and 
freezing.   The unopened vi als can be stored at room temperature (up to 25oC, 77oF) and room light for up 
to [ADDRESS_730939] be completed within 24 hours of preparation. I f not used 
immediately, the infusion solution may be stored under refrigeration conditions (2°C to  8°C, 36°F to 46°F) 
for up to 24 hours, and a maximum of 8 hours of the total 24 hours can be at  room temperature (20oC to 
25oC, 68oF to 77oF) and room light. The maximum of [ADDRESS_730940] (IP) of this 
trial and will be provided by [CONTACT_414] -Myers Squibb  (BMS) .  Chemotherapy with docetaxel, paclitaxel, 
doxorubicin, cyclophosphamide, trastuzumab, or pertuzumab is considered Non-IP as it represents routine 
or standard of care treatment for the respective patient population. Chemotherapy will not be provided by 
[CONTACT_556490].  
IP treatment  
 
Nivolumab : Nivolumab will be given at 360mg intravenously (IV) on Day 1 of every 21 day cycle during 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  30 Cycle 1 -4.   
 
Non-IP treatment  
 
Cohort 1: TNBC or HR -positive/HER2 -negative :  
 
Paclitaxel:  Paclitaxel will given at 80 mg/m2 IV weekly x 12  during Cycle 1 -4. 
Doxoru bicin:  Doxorubicin will be given at 60 mg/m2 IV every two  weeks x 4  during Cycle 5 -8.  
Cyclophosphamide : Cyclophosphamide will be given at 600 mg/m2 IV every two  weeks x 4  during Cycle 
5-8. 
 
Doxorubicin and Cyclophosphamide will be administered with G-CSF support.  
 
 
Cohort 2:  HR-positive/HR -negative and HER2 -positive :  
 
Docetaxel:  Docetaxel will be given at 75 mg/m2 IV every three weeks x 4  during Cycle 1 -4. 
Paclitaxel  (may be substituted for Docetaxel): Paclitaxel will be given at 80 mg/m2 IV weekly x 12 during 
Cycle 1 -4. 
Trastuzumab *: Trastuzumab will be given at 8 mg/kg IV on day 1 of C ycle 1 and then 6 mg/kg IV on day 1 
of Cycle 2-4 every three weeks.  
Pertuzumab : Pertuzumab will be given at 840 mg IV on day 1 of C ycle 1 and then 420 mg IV on day 1 of 
Cycle  2-4 every three weeks.  
Doxorubicin:  Doxorubicin will be given at 60 mg/m2 IV every two  weeks x 4  during Cycle 5 -8.  
Cyclophosphamide : Cyclophosphamide will be given at 600 mg/m2 IV every two  weeks x 4  during Cycl e 
5-8. 
 
Doxorubicin and Cyclophosphamide will be administered with G -CSF support.  
*Trastuzumab biosimilar is allowed.   
 
5.2.[ADDRESS_730941] with fever, chills, 
rigors, headache, rash, pruritus, arth ralgias, hypotension, hypertension, bronchospasm, or other allergi c-
like reactions. All Grade 3 or 4 infusion reactions should be reported as an SAE if it meets the criteria. 
Infusion reactions should be graded according to NCI C TCAE (Version 5.0) guidelines.  
 
Treatment recom mendations are provided below:  
 
For Grade 1 symptoms : (Mild reaction; infusion interruption not indicated ; intervention not indicated).  
  
• Remain at bedside and monitor subject until recovery from symptoms. The following prophylactic 
premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) 
and/or acetaminophen/paracetamol [ADDRESS_730942] 30 minutes before additio nal 
nivolumab administrations.  
 
For Grade 2 symptoms : (Moderate reaction requires therapy or inf usion interruption but responds  
prompt ly to symptomatic treatment [eg, antihistamines, non -steroidal anti -inflammatory drugs, narcotics,  
corticosteroids, IV fluids]; prophylactic medications indicated for ≤ 24 hours).  
  
• Stop the nivolumab infusion, begin an IV infusion of normal saline, and t reat the subject with 
diphenhydramine 50 mg IV (or equivalent) and/or acetaminophen/paracetamol 325 to 1000 mg; 
remain at bedside and monitor subject until resolution of symptoms. Corticosteroid therapy may 
also be administered as appropriate. If the infus ion is interrupted, then restart the infusion at 50% 
of the original infusion rate when symptoms resolve; if no further complications ensue after 30 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  31 minutes, the rate may be increased to 100% of the original infusion rate. Monitor subject closely. If 
sympt oms recur, then no further nivolumab will be administered at that visit.  
 
• For future infusions, the following prophylactic pre -medications are recommended: 
diphenhydramine 50 mg (or equivalent) and/or acetaminophen [ADDRESS_730943] 30 minutes before nivolumab infusions. If necessary, corticosteroids (up to 
25 mg of SoluCort ef or equivalent) may be used.  
  
For Grade 3 or 4 symptoms : (Severe reaction, Grade 3: prolonged [ie, not rapi[INVESTIGATOR_86025]/o r brief interruption of infusion]; recurrence of symptoms following initial 
improvement; hospi[INVESTIGATOR_14138] [eg, renal impairment, pulmonary 
infiltrates]. Grade 4: Life -threatening; pressor or ventilatory support indicate d).  
 
• Immediately discontinue infusion of nivolumab. Begin an IV infusion of normal saline  and treat the 
subject as follows: Recommend bronchodilators, epi[INVESTIGATOR_238] 0.2 to 1 mg of a 1:1000 solution for 
subcutaneous administration or 0.1 to 0.25 mg of a 1:10 ,000 solution injected slowly for IV 
administration, and/or diphenhydramine 50 mg IV with methylprednisolone 100 mg IV or 
equivalent), as needed. Subject should be monitored until the Investigator is comfortable that the 
symptoms will not recur. Nivolumab will be permanently discontinued.  Investigators should follow 
their institutional guidelines for the treatment of anaphylaxis.  Remain at bedside and monitor 
subject u ntil recovery of the symptoms.  
  
In case of late -occurring hypersensitivity symptoms (e g, appearance of a localized or generalized pruritus 
within 1 week after treatment), symptomatic treatment may be given (eg, oral anti histamine or 
corticosteroids).  
5.3 Dosage Modification  
 
Dose reductions or dose escalations for nivolumab are not permitted.  
5.3.1  Nivolumab Dose Delay Criteria for Study Treatment  
 
Study drug administration should be delayed for the following:  
 
• Grade 2 non -skin, drug -related AE, with the exception of fatigue  
• Grade 2 drug -related creatinine  
• Grade 3 skin, drug -related AE  
• Grade 3 drug -related laboratory abnormality, with the following exceptions:  
o Grade 3 lymphopenia or asymptomatic amylase or lipase does not require dose delay  
• Any adverse event, laboratory abnorm ality, or intercurrent illness , which in the judgment of  the 
investigator, warrants delaying the dose of study medication.  
• Dose delay for AST, ALT, or Total Bilirubin abnormalities should be managed as follows:  
o If a participant has a baseline AST, ALT, or Bilirubin that is within normal limits, delay  
dosing for drug -related Grade ≥ [ADDRESS_730944], ALT, or Bilirubin within the Grade 1 toxicity range,  delay 
dosing for drug -related Grade ≥ [ADDRESS_730945] (whichever is lower)  
 
Participants who require delay of study treatment shoul d be re -evaluated weekly or more frequently if 
clinically indicated and resume study treatment when re -treatment criteria are met (See Section 5.3) .  See 
also Appendix 3  (Algorithms for Management of Side Effects of Nivolumab) for guidance on appropriate 
management and follow -up of adverse events.  
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  32  
5.3.2   Criteria for Discontinuation of Nivolumab  
 
Study treatment should be permanently discontinued for the following:  
• Any Grade 2 drug -related uveitis, eye pain or blurred vision that does not respond to topi[INVESTIGATOR_120996] 1 severity within the re -treatment period O R requires systemic 
treatment.  
• Any Grade 3 non -skin, drug -related AE lasting > 7 days or recurs : 
o Grade 3 drug -related uveitis, pneumonitis, bronchospasm, neurologic to xicity, 
hypersensitivity reaction, or infusion reaction of any dura tion requires discontinuation.  
o Grade 3 drug -related endocrinopathies, adequately controlled with only physiologic 
hormone replacement do not require discontinuation. Adrenal insufficiency requires 
discontinuation regardless of control with hormone replacement.  
o Grade 3 drug -related laboratory abnormalities do not require treatment discontinuation 
except:  
  Grade 3 drug-related thrombocytopenia > [ADDRESS_730946] (LFT) abnormality that meets the following 
criteria require discontinuation  
 AST or ALT >[ADDRESS_730947] for >2weeks  
 AST or ALT >[ADDRESS_730948] irrespective  of duration  
 Total  bilirubin  >[ADDRESS_730949] for those  participants  with normal  total bilirubin  at 
entry or > [ADDRESS_730950] for participants with elevated bilirubin at study entry, 
irrespective of duration  
• Any Grade 4 drug -related adverse event or laboratory abnormality, except for the following 
events which do not r equire discontinuation:  
o Grade 4 neutropenia ≤7 days  
o Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase  
o Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with 
clinical sequelae and are corrected with supplemen tation/appropriate management 
within 72 ho urs of their onset  
o Grade 4 drug -related endocrinopathy adverse events, such as, hyper - or 
hypothyroidism, or glucose intolerance, which resolve or are adequately controlled with 
physiologic hormone replacement (co rticosteroids, thyroid hormones) or glucose -
controlling agents, respectively, may not require discontinuation after discussion with 
and approval from the  Sponsor’s Medical Monitor or designee.  
• Any event that leads to delay in dosing lasting >6 weeks from the previous dose requires 
discontinuation, with the following exceptions:  
o Dosing delays to allow for prolonged steroid tapers to manage drug -related adverse 
events are allowed.  
o Dosing delays lasting > 6 weeks from the previous dose that occur for non -drug-related 
reasons may be allowed if approved by [CONTACT_16049]’s  Medical Monitor or designee.  
• Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of the 
Investigator, presents a substantial clinical risk to the participan t with continued study 
treatment.  
 
5.3.3    Criteria To Resume Treatment with  Nivolumab  
 
Participants may resume treatment with study treatment when the drug -related AE(s) resolve to ≤ Grade 1 
or baseline value, with the following exceptions:  
 
• Participants may resume treatment in the presence of Grade 2 fatigue.  
• Participants who have not experienced a Grade 3 drug -relate d skin AE may resume treatment in 
the pres ence of Grade 2 skin toxicity.  
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  33 • Participants with baseline Grade [ADDRESS_730951], 
ALT, or Total Bilirubin.  
• Participants who require dose delays for drug -related increase d AST, ALT, or Total Bilirubin may 
resume treatment when hepatic parameters are at baseline or Grade 1 and after discussion with 
Sponsor’ s Medical Monitor or designee.  
• Participants with AST, ALT, or Total Bilirubin values meeting discontinuation should have treat ment 
permanently discontinued.  
• Drug -related pulmonary toxicity, diarrhea or colitis must have resolved to baseline before treatment 
is resumed. Participants with persistent Grade [ADDRESS_730952] 1 month may be eligible for retreatment if discussed with and approved by [CONTACT_2728]’s  
Medical Monitor or designee.  
• Participants w ith drug -related endocrinopathies adequately controlled with only physiologic 
hormone replacement may resume treatment after consultation with Sponsor’s  Medical Monitor or 
designee. Adrenal insufficiency requires discontinuation regardless of control with hormone 
replacement.   
 
5.3.4  Recommendations for Chemotherapy Delays and M odifications  
 
In the opi[INVESTIGATOR_871], if a toxicity is considered to be attributable solely to one component of the 
study treatment and the dose of that component is delayed or modified in accordance with the guidelines 
below, the other component may be administered if there is no contraindication.  
 
Table 7  Dose Modification Levels for Docetaxel / Paclitaxel  
Level  Dose Level 0 
(starting dose)  
(mg/m2) Dose Level -1 
(mg/m2) Dose Level -2 
(mg/m2) Dose Level -3 
(mg/m2) 
Docetaxel  
(mg/m2) 75 60 50 Discontinue  
Paclitaxel  
(mg/m2) 80 60 50 Discontinue  
 
General dose modification guidelines : 
 
• If a taxane -related hypersensitivity reaction occurs despi[INVESTIGATOR_95922]-medication, treatment  as medically 
indicated will be instituted.  
 For hypersensitivity reaction less than CTCAE Grade 3, continuation of  
docetaxel/paclitaxel is at the Investigator’s discretion.  
 If Grade 4 hypersensitivity is experienced, docetaxel/pacl itaxel must be  permanently 
discontinued.  
 If the taxane is discontinued, an alternative taxane may be substituted (nab -paclitaxel 
or docetaxel if paclitaxel was discontinued).  Dosing and schedule of alternative taxane 
is as per institutional standard of ca re.    
• Taxane -related fluid retention will be treated as per the Investigator’s discretion.  
• For HER2 -positive tumors, i f the taxane must be discontinued before completion of the scheduled 
cycles, the  remai ning trastuzumab and pertuzumab  can be administered . 
• For patients who are dose reduced due to Grade 2 or Grade 3 toxicity, they may return to the 
starting dose level if the AE returns to baseline or Grade 1, per discretion of the Investigator.  
• Dose level reductions that are below the recommended level in the tables can be made per 
discretion of the Investigator.    
 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  34 See Table 8 for the management of taxane -related neurosensory toxicity and Table 9  for taxane -related 
musculoskeletal pain. Instructions for management of all other toxicities related to docetaxel/paclitaxel are 
listed in Table 1 1. 
 
 
Table 8 Dose modifications for taxane -related neurosensory toxicity  
 
Paresthesias/Dysesthesias  1 – 7 Day s Duration  Persistent for >7 Days  
Grade 1  
 Maintain docetaxel/paclitaxel 
dose  Maintain  
docetaxel/paclitaxel dose  
Grade 2  
 Maintain docetaxel/paclitaxel 
dose Decrease  
docetaxel/paclitaxel one 
dose level 
Grade 3a 
 First epi[INVESTIGATOR_1865]:  
Decrease docetaxel/paclitaxel 
one dose level 
 
Second epi[INVESTIGATOR_1865]:  
Decrease  docetaxel/paclitax el 
two dose levels Decrease  docetaxel/paclitax el 
two dose levels  
OR  
Discontinue  
docetaxel/paclitaxel  
 
a For persistent paresthesias/ dysesthesias that are disabling or life -threatening, docetaxel/paclitaxel  should 
be discontinued.  
 
 
Table 9 Dose modifications for taxane -related musculoskeletal pain not controlled by [CONTACT_556491]  1 – 7 Days Duration  Persistent for >7 Days  
Grade 1  
 Maintain docetaxel/paclitaxel 
dose  Maintain  
docetaxel/paclitaxel dose  
Grade 2  
 Maintain docetaxel/paclitaxel 
dose Decrease  
docetaxel/paclitaxel one 
dose level 
Grade [ADDRESS_730953] epi[INVESTIGATOR_1865]:  
Decrease docetaxel/paclitaxel 
one dose level 
 
Second epi[INVESTIGATOR_1865]:  
Decrease  docetaxel/paclitax el 
two dose levels  
 First epi[INVESTIGATOR_1865]:  
Decrease docetaxel/paclitaxel 
one dose level 
OR 
Decrease  docetaxel/paclitax el 
two dose levels  
 
Second epi[INVESTIGATOR_1865] : 
Discontinue docetaxel/paclitax el 
 
a Use of analgesics can be used  to maintain dose of docetaxel/paclitaxel if possible.  
 
 
Table 10  Dose Modification Levels for D oxoru bicin / Cyclophosphamide  
 
Level  Dose Level 0 
(starting dose)  
(mg/m2) Dose Level -1 
(mg/m2) Dose Level -2 
(mg/m2) Dose Level -3 
(mg/m2) 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  35  
Doxorubicin  
(mg/m2) 60 50 40 Discontinue  
Cyclophosphamide  
(mg/m2) 600 500 400 Discontinue  
 
• For patients who are dose reduced due to Grade 2 or Grade 3 toxicity, they can return to the starting 
dose if the AE returns to baseline or Grade 1, per discretion of the Investigator  
• Dose level reductions that are below the recommended level in the table s can be made per 
discretion of the Investigator.    
 
 
Table 1 1 Dose modifications and delays for docetaxel / paclitaxel / doxorubicin / cyclophosphamide  
 
NCI CTCAE v 5.0 [Category]  
Grade  
  Modifications for AEsb 
 
HEMATOLOGICAL:  
Neutrophil count decreased  
Grades 2, 3, 4   Hold until ≥ 1500/mm3 
 
If recovery takes:  
• 1-3 wks: maintain dose 
and add G -CSF 
 
If previously receiving G -CSF 
and recovery  takes:  
 
• 1 wk: maintain dose  
• 2-3 wks: decrease  one 
dose level  
 
Platelet count decreased  
Grades 2, 3   Hold until ≥ 75,000/mm3. 
 
If recovery takes:  
• 1 wk: maintain dose  
• 2-3 wks: decrease one 
dose level  
 
Grade 4   Decrease one dose level  
BLOOD AND LYMPHATIC SYSTEM DISORDERS : 
Febrile Neutropenia  
Grade 2   Maintain dose  
Grade 3 (first epi[INVESTIGATOR_1865])   Maintain dose and add G -CSF 
Grade 3 (subsequent epi[INVESTIGATOR_1841])   Decrease one dose level  
Grade 4 (first epi[INVESTIGATOR_1865])   Decrease one dose level  
Grade 4 (subsequent epi[INVESTIGATOR_1841]_   Decrease two dose levels or 
discontinue  
GASTROINTESTINAL DISORDERS (if related to chemotherapy) : 
Diarrhea    
Grade 2   Maintain dose  
Grade 3   Decrease  one dose level  
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  36 Grade 4   Decrease two  dose level s or  
discontinue  
Mucositis    
Grade 2   Maintain dose  
Grade 3   Decrease  one dose level  
Grade 4   Decrease two  dose level s or  
discontinue  
Vomiting (despi[INVESTIGATOR_556447])    
Grade 2   Maintain dose  
Grade 3   Decrease one dose  level 
Grade 4   Decrease two dose levels or 
discontinue  
HEPATIC FUNCTION:  
Bilirubin or AST or ALT increased  
Grade [ADDRESS_730954] 
returned to  ≤ grade 1.  Then 
decrease  one dose level . 
Grade [ADDRESS_730955] 
returned to  ≤ grade 1.  Then 
decrease  one do se level . 
Grade 4   Discontinue  
OTHER  CLINICALLY SIGNIFICANT AEs:  
Grade 3   Decrease one dose level  
Grade 4   Decrease two dose levels or 
discontinue  
 
 
Table 12  Left ventricular dysfunction  
 
Adverse Event  Grade  
1 2 3 4 
Left ventricular 
systolic 
dysfunction  - - Symptomatic due to 
drop in ejection fraction 
responsive to 
intervention  Refractory or poorly 
controlled heart failure 
due to drop in ejection 
fraction; intervention 
such as ventricular 
assist device, 
intravenous 
vasopressor support, 
or heart transplant 
indicated  
 
For symptomatic heart failure, treatment includes management p er standard evidence -based guidelines 
and management of any concurrent conditions (such as hypertension) and fluid management with diuretic 
therapy as needed.   
 
For asymptomatic decline to an LVEF <40% and at least 15 percentage points to LVEF <50%, doxor ubicin 
and cyclophosphamide should be held and repeat imaging with TTE or MUGA performed in two to four 
weeks.  If LVEF is improved to >50%, then treatment can be resumed.   
Dose modifications for trastuzumab and pertuzumab  
 
No dose reduction is recommende d. In case of severe toxicity probably related to these compounds, 
treatment should be discontinued. If toxicity is recovered within three weeks to Grade 1, a restart of 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  37 treatment should be considered  at the discretion of the treating investigator .  
 
If the patient misses a dose of trastuzumab or pertuzumab for any cycle, i .e., the  two sequential 
administration times are 6 weeks or more apart, a re -loading dose of 8 mg/kg of trastuzumab and 
pertuzumab [ADDRESS_730956] in the decision as to whether to initiate, continue or discontinue 
therapy based on LVEF assessment in asymptomatic patients.  
5.4 Preparation /Handling/Storage/Accountability  
 
The investigational product should be stored in a secure area according to  local regulations.  It is the 
responsibility of the investigator to ensure that the investigational produce is only dispensed to study 
participants.  The investigational product must only be dispensed from official study sites by [CONTACT_556492].  The product storage manager should ensure that the study 
treatment is stored in accordance with the environmental conditions (temperature, light, and humidity) as 
determined by [CONTACT_20444].  If concerns regarding the quality or appeara nce of the study treatment arise, the study 
treatment should not be dispensed and contact [CONTACT_556493].  
 
Study treatment not supplied by [CONTACT_53972].  
 
Investigational product documentation must be  maintained that includes all processes required to ensure 
drug is accurately administered.  This includes documentation of drug storage, administration, and as 
applicable, storage temperatures, reconstitution, and use of required processes (e.g., required  dilutents, 
administration sets).  
5.[ADDRESS_730957] Treatment Compliance Monitoring  
 
Study treatment will be administered in the clinical facility.  Treatment compliance will be monitored by [CONTACT_556494]’s medical record and eCRF.   
5.6 Concomitant Therapy  
 
Concomitant therapy includes any medication (e.g., prescription drugs, over -the-counter drugs, herbal or 
homeopathic remedies, nutritional supplements) used by a patient from [ADDRESS_730958] b e recorded on the CRF.  
 
5.6.1   Prohibited Therapi[INVESTIGATOR_556448] (unless authorized to treat a drug related adverse 
event):   
 
• Immunosuppressive agents  
• Immunosuppressive doses of systemic corticosteroids  
• Traditional herbal medicines: These therapi[INVESTIGATOR_513703] -drug interactions that may cause or confound th e assessment of toxicity  
• Concurrent use if antiviral therapy containing IFN  
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  38 • Excessive alcohol intake should be avoided (occasional to moderat e use is permitted)  
 
5.6.2   Permitted Therapi[INVESTIGATOR_556449]:  
 
• Prophylactic or therapeutic antic oagulation therapy (such as low -molecular weight heparin or 
warfarin at a stable dose level)  
• Inactive influenza vaccinations during influenza season  
• Inhaled corticosteroids for chronic obstructive pulmonary disease  
• Mineralocorticoids (e.g., fludrocortisone)  
• Low-dose corticosteroids for subject s with orthostatic hypotension or adrenocortical insufficiency  
• Bisphosphonates for prevention of ske letal related events  
 
Subject s who experience infusion -associated symptoms may be treated symptomatically with 
acetaminophen, ibuprofen, diphenhydramine, and/or famotidine or another H2 -receptor antagonist per 
standard practice. Serious infusion -associated  events manifested by [CONTACT_27926], hypotension, wheezing, 
bronchospasm, tachycardia, reduced oxygen saturation, or respi[INVESTIGATOR_226800] (e.g., supplemental oxygen and β2 -adrenergic agonists).  
 
6 Study Procedures  
6.1 Study Calendar /Study Schedule of Events  
 
See Study Schedule of Events on next page .  
 
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in writing by [CONTACT_120776].  39 Study Activity  Screening 
Phasea  
Treatment Phase   
(Cycle 1 -4 = 21 days ; Cycle 5 -8 = 14 days )b After E nd of 
Treatment  and 
Prior to 
Surgery  
 
Time of 
Surgery   
 
 
 
Post Surgery1 
 
  
 
End of 
Study 
Follow -
upj 
Treatment Cycle  
 
  
 
 
 
-60 to -1 
(days)  
 
 
 
 
 
 1 2  3 4  
 
 
 
5 6  
 
 
 
7  
 
 
 
8 
 
 
 
 
  
 
 
≤ [ADDRESS_730959] 
treatment  
  
 
 
 
  
Scheduling Window  
 
 
 ± 3 
days 
 
 ± 3 
days 
 
 ± 3 
days 
 
 ± 3 
days 
 
   
 
 
± 3  
days  
 
 
± 3  
days 
 
  
 
 
± 3  
days  
 
 
± 3  
days 
 
Clinical Pr ocedures/Assessments   
Informed Consentc X      
    
   
Inclusion/Exclusion 
Criteriad X      
    
   
Demographics and 
Medical Histor ye X      
    
   
Prior and Concomitant 
Medications Reviewf X X X X X X X X X  
   
Physical Examinationg X X X X X X X X X  
   
ECOG Performance 
Status  X X X X X X X X X  
   
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in writing by [CONTACT_120776].  40 Vital Signs and Weightg X X X X X X X X X  
   
Heightg X      
    
   
Neoadjuvant Treatment 
Administrationh  X X X X X X X X  
   
Review Adverse Eventsi  X X X X  
X X  
X  
X  
   
 
Follow -up for recurrence -
free survivalj 
       
    
   
X 
(up to two 
years)  
Laboratory Procedures/Assessments   
Pregnancy Test – Urine 
or Serum β -HCG (women 
of childbearing 
potential )k  
X 
(within 24 hours 
prior to start of 
nivolumab)  
 X X X X  
 
X  
 
X X  
 
X  
   
CBC with Differentiall X X X X X  
X  
X X  
X  
   
Comprehensive Serum 
Chemistry Panel (Blood 
Chemistry and Liver 
Function Tests)l X X X X X   X X X X  
   
TSH, free T3 (or total 
T3), and free T41 X     X     
   
HBV and HCV testingl  X          
   
Urinalysisl X          
   
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in writing by [CONTACT_120776].  41  
 12-Lead EKGm X       
   
   
Cardiac echo (TTE) or 
MUGA scann X 
(within 60 
days)  Continue q 3 months   
   
Treatment   
Nivolumab  (Day 1  of 
Cycle 1 -4)o  X X X X  
    
   
Chemotherapyp  X X X X  
X  
X X  
X  
   
Radiationq        
   
 X  
Adjuvant therapyr         
   
 X  
Tumor Assessment and Imaging Procedures  
Clinical tumor 
assessments  
X 
 X X X X  
X  
X X  
X  
    
Imaging testst X 
(within 60 
days)        
  
  
X    
Tumor Biopsies/Archival Tissue Collection/Blood for Correlative Studies   
Archival or Newly 
Obtained Tissue 
Collectionu X 
(within 60 
days)     X 
(optio
nal)   
   X 
(if 
residual 
disease)  
    
Peripheral B lood 
Collectionv  X    
  
X  
   
X  
   
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in writing by [CONTACT_120776].  42  
 
 
1 Within 3 months (± 14 days)  post-surgery  
a Screening  Phase: All screening evaluations must be completed and reviewed to confirm that subjects meet all inclusion criteria and do n ot meet any of the 
exclusion criteria.   
b Treatment Phase : Assessments should be performed prior to dosing on the visit d ay unless  otherwise indicated. For Cycle [ADDRESS_730960] dose of treatment drug at baseline (Cycle 1, Day 1) and following the pre -defined visit schedule throughout the treatment period ( ± 3 days).  
For Cycle [ADDRESS_730961] dose of treatment drug at baseline (Cycle 1, Day 1) and following the pre -defined visit schedule 
throughout the treatment period ( ± 3 days).   
c  Informed Consent:  Informed consent must be obtained prior to any protocol required screening assessments being performed, which i s not performed as part of 
standard  routine care.  
d Inclusion Criteria: See Section 4.1  for inclusion criteria and Section 4.2 for exclusion criteria.  
e Demographics and Medical History: Medical history includes clinically significant diseases that are currently active or that were active, including major surgeries, 
within the previous 10 years, any cancer history (including prior cancer therapi[INVESTIGATOR_398033]) and reproductive status. Demographic data includes age, sex, 
stratification factors, and self -reported race/ethnicity.  
f Any concomitant medications and treatments will be recorded from [ADDRESS_730962]/chest wall, axilla, supra - and infraclavicular region, height, weight, blood pressure and pulse 
rate is required.  This should be done within 30 days prior to enrollment  (Cycle 1 Day 1) . Directed physical examinations including clinical assessment of tumor, 
blood pressure, weight and pulse rate can be performed at subsequent visits.  
h. See Section 1.4  for dose and schedule  of treatment administration with nivolumab (IP), c hemotherapy, and/or HER2 -targeted therapy.  At each visit, prior to IP 
dispensation, an AE and laboratory -based assessment must be performed by [CONTACT_556495], reduction , or discontinuation  
according to the protocol . 
i AEs/SAEs must be reported from the date of signature [CONTACT_556530] a minimum of [ADDRESS_730963] be reported within 24 hours of site awareness (see Section 8.3  for further instructions). AEs fulfilling the criteria for expedi ted 
reporting have to be treated according to the reporting procedures described in Section 8.3 including a submission to the Sponsor within 24 hours of awareness.  
j After surgery , subjects will be followed  every 3 months ( ± 14 days)  thereafter until end of study which is up to 2 years.  Subjects will be followed for the 
occurrence of local or distant recurrence and/or death.  If an in -person visit is unable to be performed, a telemedicine encounter  (video or telephone) is allowed.   
k Women of child -bearing potential must have a pregnancy test every [ADDRESS_730964] (minimum sensitivity 25 
IU/L or equivalent units of HCG) within 24 hours prior to the start of  study treatment . 
l Laboratory te sts:  Hematology includes hemoglobin, WBC, absolute neutrophil count, and platelet count. Blood chemistry inc ludes AST/ALT, alkaline 
phosphatase, sodium, potassium, magnesium, total calcium, total bilirubin, blood urea nitrogen (or urea), serum creatinine,  and albumin .  Hepatitis B and C 
screening is required. Thyroid Stimulating Hormone (TSH) , free T3 (or total T3), and free T4 will be checked at screening and during Cycle [ADDRESS_730965] of care, and may require an endocrine consult and additional testing.  Additional  hematology/chemistry 
panels may be performed as clinically indicated. INR and aPTT will be done during screening period and afterward as clinicall y indicated.  Laboratory tests for 
screening o r entry into the study should be performed within 30 days prior to enrollment  (Cycle 1 Day 1 ).  
l Urinalysis will be done at screening and afterward as clinically indicated. Urinalysis includes specific gravity, pH, glucose, protein, ketones, and blood.  L aboratory 
tests for screening or entry into the stu dy should be performed within 30 days prior to enrollment  (Cycle 1 Day 1 ).  
S17-[ZIP_CODE]  
Version 6.0 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as aut horized in writing by [CONTACT_120776].  43 m A 12 -lead EKG is required within 30 days prior to enrollment  (Cycle 1 Day 1) . Subsequent EKGs may be performed as clinically indicated. EKGs for each 
subjec t should be obtained from the same machine wherever possible.  EKG recordings must be performed after the subject  has been resting in a supi[INVESTIGATOR_49844] 10 minutes.   
n LVEF assessment by [CONTACT_556496] 60 days prior to enrollment  (Cycle 1 Day 1) . The same method should be used throughout the study for each 
subject  if possible .  LVEF assessment will be performed every three months (±7 days) , during study t reatment  (Cycle 1 -8). For subjects with HER2 -positive 
tumors, LVEF assessment  will continue every three months  (±7 days)  thereafter  while receiving adjuvant T -DM1, trastuzumab, and/or pertuzumab.  
o Nivolumab  (IP) will be administered at each Day 1 (±3 days ) onsite visit during Cycle [ADDRESS_730966] be performed by [CONTACT_556497].    
p See Section 1.4 for dose and schedule  of treatment administration with chemotherapy and/or HER2 -targeted therapy.  At each visit, prior to IP dispensation, an 
AE and laboratory -based assessment must be performed by [CONTACT_556495], reduction , or discontinuation  according to the 
protocol . 
q Radiation: Post-mastectomy radiotherapy  as per institutional guidelines  
r See Section 1.4  for postoperative adjuvant therapy (regarding endocrine therapy, capecitabine, T -DM1, trastuzumab, and pertuzumab)  
s Clinical evaluation, with a bidimensional measurement of the tumor, will be performed every three weeks during Cycle 1 -4 and every two weeks during Cycle 
5-8. The presence  of erythema, edema, and/or peau d’orange should also be noted.  For subject s with no pa lpable mass, changes in clinically evaluable skin 
criteria (erythema, edema, peau d’orange), will be considered as response criteria . 
t Tumor assessments performed as standard of care and within 60 days prior to enrollment  (Cycle 1 Day 1 ).  Initial imaging  assessments must include bilateral 
mammogra m and/or bilateral ultrasound. Bilateral breast MRI is optional. I maging must also be performed at screening to rule out distant disease. CT scans 
(with IV contrast and oral contrast unless contraindicated) of the chest, abdomen, and pelvis or Positron emission tomography  (PET)/CT may be used.  If a CT 
scan for tumor ass essment is performed as part of a PET/CT, the CT acquisition must be consistent with the standards for a full -contrast diagnostic CT scan.  
MRI scans of the chest, abdomen, and pelvis may be used in subject s for whom CT scans with contrast are contraindica ted (i.e., subject s with contrast allergy or 
impaired renal clearance). A bone scan or PET scan should also be performed to evaluate for bone metastases  if there is clinical suspi[INVESTIGATOR_556446] . 
Re-evaluation of th e primary tumor by [CONTACT_556498], breast ultrasound, and/or breast MRI should be performed after the end of Cycle 8 
(prior to surgery ).  
u FFPE archival tumor specimen  or a fresh core biopsy  (preferred)  (optimally at least 2 cores) within 60 days prior to enrollment  (Cycle 1 Day 1)  is required. An 
optional core biopsy  can be obtained at end of Cycle 4 (± 7 days) for correlatives.  Tissue specimen will be obtained at the time of surgery  if there is residual 
disease.  A tumor block is preferred, however if a block is not  feasible, a minimum of [ADDRESS_730967] ion: Maximum of [ADDRESS_730968]  shows progressive disease (increase in tumor area by 25% or detection of new lesion) or treatment 
has to be discontinued due to toxicity, subject s wish, or other reasons, further treatment decisions have to be 
made individually by [CONTACT_941] I nvestig ator.  
 
Immediate surgery (in the case of given operability), radiotherapy (in the case of inoperability) or continuation 
of systemic treatment have to be discussed with the subject . It is recommended to the investigator to follow 
as closely as possible pr otocol guidelines for surgical or radiation treatment as well as for postsurgical 
systemic treatment as the subjec t still remains a study participant and will be included in the intent -to-treat 
analysis.   Only a subject  who has withdrawn her consent for da ta collection will be excluded from the analysis.  
 
With regard to continuation of neoadjuvant systemic therapy, the following recommendations are made:  
 
For HER2 -negative disease, i f tumor progression or intolerable toxicity occurs during the taxane -base d cycles  
(paclitaxel or docetaxel) , subjects may skip the remaining taxane cycles and continue with doxorubicin and 
cyclophosphamide),  
 
For HER2 -positive disease, i f tumor progression or intolerable toxicity occurs during the taxane -based cycles  
(paclitaxe l or docetaxel) , subjects may skip the remaining taxane cycles and continue with trastuzumab or 
pertuzumab.  
 
For HER2 -positive disease, i f tumor progression or intolerable toxicity occurs during treatment with 
trastuzumab and pertuzumab, subjects may skip the remaining cycles of trastuzumab and pertuzumab and 
continue with the taxane (paclitaxel or docetaxel).  
 
For both HER2 -negative and HER2 -positive disease, if tumor progression or intolerable toxicity occurs during 
the anthracycline -based cycles (doxorubicin and cyclophosphamide), systemic treatment should be 
discontinued and subject s should undergo immediate local treatment.  
 
The reason and date of chemotherapy discontinuation for all subject s will be documented on the Case Report  
 Form (e.g. progressive disease, death, adverse event, withdrawal of consent, lost to follow -up, etc.).   
6.[ADDRESS_730969] phase (adjuvant treatment)  will include radiotherapy according to institutional practice.   Radiotherapy 
targets should include the chest wall and supraclavicular, infraclavicular, and internal mammary chain nodes.  
Subject s with HR -positive tumors sh ould receive a minimum  of 5 years of adjuvant endocrine therapy.  Choice of 
endocrine therapy is at the discretion of the investigator.   
 
For HER2 -positive tumors, patients with residual disease after neoadjuvant therapy may receive ado -
trastuzumab emtans ine (T -DM1) in the adjuvant setting for 14 cycles49.  Another option is to continue 
trastuzumab with or without pertuzumab to complete one year  of HER2 -directed therapy35.  For patients with 
pathologic complete response (no residual disease), adjuvant trastuzumab can be continued with or without 
pertuzumab to complete one year of HER2 -directed therapy.  The choice of  adjuvant therapy is at the 
discretion of the investigator.  
 
The u se of adjuvant capecitabine for [ADDRESS_730970] -Treatment Follow -up/End of Treatment/End of Study Visits  
 
6.4.[ADDRESS_730971] will be contact[CONTACT_556499] a member of the study team (unless there is a clinic visit in the 
same time frame).   
 
After neoadjuvant treatment and surgery, all subjects will be followed  up to two years  for the occurrence of 
local or distant recurrence and death.  A visit at the trial site should be performed and documented every 
three months  (±14 days)  up to two years.   If an in -person visit is unable to be performed, a telemedicine (video 
or telephone) encounter  is allowed.   
 
End of Study Visit  
 
Subject ’s end of study visit is the last formal study visit or last formal contact [CONTACT_556500] -up.  End of study (EOS) is defined as 24 
months after study treatment .    
Subjects  will no longer be formally followed after co mpletion of the end of study  visit, unless adverse event(s) 
occur that require subsequent follow -up (i.e. unresolved AEs). All adverse events, both serious and non -
serious, and deaths that are encountered during the study and within [ADDRESS_730972] to follow -up; survival 
data will be obtained by [CONTACT_556501].  
 
6.4.[ADDRESS_730973] -Study Access  
 
At the end of the study period, BMS  will not continue to supply study drug to subjects/investigators unless the 
Sponsor -Investigator chooses to extend their study. The investigator is responsible to ensure that the subject 
receives appropriate standard of care or other appropriate treatment  in the independent medical judg ment of 
the Investigator to treat the condition under study.  
 
 
S17-[ADDRESS_730974] 2 core needle biopsies 
are preferred  (prior to first dose of nivolumab and chemotherapy). Another optional core biopsy will be 
obtained during treatment at end of Cycle 4  (completion of nivolumab therapy) .  A tumor block is preferred, 
however if a block is not feasible, a minimum of [ADDRESS_730975] a 
recommended tissue thickness of 5 -10 microns . 
If only minute tissue is present ( recuts listed in order of priority):  
1 USS 5 microns for H&E  
2 USS 5 microns for PD -L1 IHC (Charged slide)  
1 USS 5 microns for MP (Charged slide)  
6 USS 10 microns for BC360  
 
If optimal tissue is present, i.e. separate cores/separate blocks with good cellularity (recuts listed in order of 
priority):  
1 USS 5 microns for H&E  
2 USS 5 microns for PD -L1 IHC (Charged slide)  
1 USS 5 microns for MP (Charged slide)  
6 USS 10 microns for BC360  
4 USS 5 microns (back up IHC and MP  Charged slide ) 
 
For biopsies  performed at NYULMC , the pathologist may verif y the presence of leftover clinical recuts to be 
used for the study in case of limited samples.  
 
Operative specimens  
 
Tissue specimens will be obtained at  the time of surgery if there is residual disease after neoadjuvant therapy.  
A tumor block is preferred, however if a block is not feasible, a minimum of [ADDRESS_730976] tumor cellularity, (recuts listed in order of priority):  
1 USS 5 microns for H&E  
2 USS 5 microns for PD -L1 IHC (Charged slide)  
1 USS 5 microns for MP (Charged slide)  
6 USS 10 microns for BC360  
4 US S 5 microns (back up IHC and MP, Charged slide ) 
 
For surgical resections  performed at NYULMC , the pathologist may verify the presence of leftover clinical 
recuts to be used for the study in case of limited samples.  
 
6.5.2 Characterization of Tumor Immune C ells  
Immunohistochemistry (IHC)  will be used to assess the number and composition of immune cells present 
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  47 within FFPE  tumor tissue before therapy , during treatment,  and at the time of surgery19.  Expression of PD -
L1 will be measured on tumor and tumor -infiltrating immune cells. IHC analyses may include, but is not 
necessarily  limited to, the following markers: MHC class I/II, CD8, CD-20 (active B -cells)63, CD4 (helper T 
cells, regulatory T cells), FoxP3 (regulatory T cells), CD86 (M1 macrophages), CD163 (M2 macrophages), 
IL8 (associated with IBC)64, and CD68 (total macrophages).  
6.5.3 Tumor Genomic Analysis  
RNA will be extracted from tumor samples for analysis with Nanostring  assay (BC360 panel). The BC360 
panel includes [ADDRESS_730977] 
tumor microenvironment and immune response. Analysis of  data will provide information about 33 biological 
signatures including signatures based upon the validated PAM50 and Tumor Inflammation Signature (TIS) 
assays.  DNA will be extracted from tumor samples for analysis with a 580 genes NGS hybrid capture assa y.  
Tumor mutational burden  (TMB) , defined as the number of somatic, coding base substitutions and short 
insertions and deletions per megabase of genome examined , will be evaluated.  Blockade of PD -[ADDRESS_730978] of nivolumab on the T -cell repertoire in tumor specimens.  In 
addition, a nalyses of mTOR and JAK/STAT pathways, as well as inflammatory cytokines , and tumor -
associated macrophages (TAMs)65 will be performed.  
 
6.5.4 Peripheral Blood S amples  
 
Blood samples will be drawn at the time points identified in the Study Calendar ( Section 6.1 ).   
  
Key immune biomarkers will be evaluated on circulating leukocytes  to evaluate changes during PD -1 
blockade. In addition, the immune cell subset frequencies and express ion of key receptors on PBMC will be 
studied to  identify changes that occur after PD -1 blocka de. Included in the analysis are CD4/CD8 and Th1/Th2 
profiles, immunosuppressive regulatory T cells (Treg s), the development of which is promoted by [CONTACT_4002] -1/PD -
L1 ligation, dendritic cells (DC), which are important APCs, and inhibitory receptors PD -1, CTLA4, TIM-3, and 
LAG-3, which can contribute to T cell exhaustion.  Flow cytometry will be used to quantify these biomarkers.  
Sequential samples of PBMCs will be analyzed from subjects  before  and during treatment with nivolumab .   
 
Liquid biopsy enables analysi s of tumor cells and tumor DNA directly from blood. We will perform a 
comprehensive liquid biopsy evaluation  in which  whole tumor cells as well as cell -free tumor DNA are 
captured from blood  and profiled. Genetic heterogeneity is analyzed on a single cell level and compared with 
the levels of cell -free tumor DNA to determine response to therapy and predict disease recurrence. DNA from 
circulating leukocytes is used  as a control for DNA NGS and methylation.  
 
6.5.[ADDRESS_730979] ’s confidentiality, banked biospecimens and data generated from them  will be coded with 
the subject’s study ID number.  Samples will be kept in the Center for Biospecimen Research and 
Development (CBRD)  accessible only by [CONTACT_195152] -swipe. Data will be stored on password -protected computer 
systems. The key between the code and the subject’s personal identifiers will be held at the study site; the 
researchers using the biospecimens and data generated from them  will not have access to the key nor any 
personally identifying information.  Biospecimens will only be used for the purposes described here and in the 
informed consent document/patient information sheet; any other uses require additional ethical approval.   
Unless a time limitation is required by [CONTACT_240846], biospecimens will be stored 
indefinitely to allow for future research on the topi[INVESTIGATOR_498446], including research conducted during the 
lengthy drug development proces s and also post -marketing research.   Subjects can withdraw their consent 
for the use of their biospecimens at any time by [CONTACT_7328] a request to the I nvestigator, in which event any 
remaining biospecimen will be destroyed; data already generated from the bios pecimens will continue to be 
stored to protect the integrity of existing analyses. Subjects are notified in the informed consent 
document/patient information sheet that their results will not be given to them, unless required by [CONTACT_556502], in which case re sults will be returned via the I nvestigator.  
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  48  
6.5.6  Specimen Shipment  
 
See laboratory manual for full details on specimen shipment.  
 
7 Statistical Plan  
7.1 Primary Endpoint and S ample Size Determination  
 
The primary endpoint  is pathological com plete response  (pCR).  pCR is defined as no histologic evidence of 
invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after 
neoadjuvant chemotherapy.  In a retrospective analysis of 527 patients with IBC at MDACC, the pCR rates 
after neoadjuvant chemotherapy by [CONTACT_556503]2 -defined subtypes were: 7.4% in HR -
positive/HER2 -negative, 12.4% in TNBC, 15% in HR -positive/HER2 -positive, and 30.5% i n HR -
negative/HER2 -positive15.  
 
For Cohort 1 ( HER2 -negative, including TNBC and HR -positive) , a total sample size of [ADDRESS_730980] a 20% 
increase in pCR in patients who will be treated with the combination of nivolumab and neoadjuvant 
chemothe rapy compared to the 10% baseline pCR in patients treated with only neoadjuvant chemotherapy15 
with two -sided alpha of 0.05 and power of 80%  based on Fisher’s exact test.   
 
For Cohort 2 ( HER2 -positive, independent of HR status) , a total sample size of [ADDRESS_730981] a 25% increase 
in pCR in patients who will be treated with the combination of nivolumab and neoadjuvant chemotherapy 
compared to the 25% baseline pCR in patients treated with only neoadjuvant chemotherapy15 with two -sided 
alpha of 0.05 and power of 80% based on Fisher’s exact test.    
 
Descriptive statistics will be provided for efficacy endpoints. An estimated [ADDRESS_730982] s will be screened for 
eligibility to reach a goal of  52 participants.  
 
The two analysis populations will be defined as:  
• interim safety analysis population: all subjects in Cohort 2 who receive any amount of study drug (i.e. 
nivolumab).  
• efficacy evaluable population: all subjects in Cohorts 1 and 2 who receive any amount of study drug (i.e. 
nivolumab) (i.e. All -Treated Population (AT)). Analysis of efficacy endpoints will be performed on the 
efficacy evaluable population. Supportive and c orrelative analysis will be based on AT as well.  
7.2 Statistical Methods  
 
Definition of primary outcomes/endpoint:   
 
The primary endpoint will be pathological complete response  (pCR).  pCR is defined as no histologic evidence 
of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified  after 
neoadjuvant chemotherapy ( ypT0/Tis ypN0) . 
 
Definition of secondary outcomes/endpoints:  
 
Safety and tolerability of the combination of nivolumab and chemotherapy  will be determined using the 
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  49 Common Terminology Criteria for Adverse Events (CTCAE)  v5.  Dose -limiting toxicity (DLT) is defined as any 
toxicity requiring discontinuation of nivolumab as defined in Section 5.3.2 .   All on -study AEs, drug -related 
AEs, SAEs and drug-related SAEs, and /or AEs/SAEs leading to discontinuation will be tabulated as pe r NCI 
CTCAE v  5.0 criteria by [CONTACT_6657].   
 
Invasive recurrence -free interval (IRFI) will be assessed [time  frame:  up to 24 months after study entry]. This 
is defined  as the time from study entry until diagnosis of the first inv asive local, regional, or distant breast 
cancer recurrence during the [ADDRESS_730983] has no event/death but the last known 
date alive is earlier than [ADDRESS_730984]’s IRFI should be censored (at last k nown 
alive date or date of last assessment).   
 
Analytic plan for primary objective:   
 
The response rate and associated 95% confidence interval will be estimated using a uniformly minimum 
variance unbiased estimator as per Clopper -Pearson method . 
 
Analytic plan for secondary objectives:  
 
a) Safety monitoring will occur continuously in the study.  The safety endpoints are AEs graded using CTCAE 
(Version  5.0) criteria.  Safety will be assessed by [CONTACT_556504] d by 
[CONTACT_556505], including serious adverse events (SAEs). Summary statistics 
(percentage, mean, standard deviation, etc.) will be provided for the safety endpoints as appropriate.  
Sequential boundaries will be used to monitor dose -limiting toxicity rate. There will be an interim safety 
analysis in Cohort  2.  Monitoring for toxicity will follow a Bayesian -based rule for the probability that the rate 
of DLT exceeds  a maximal tolerated level of 30 %. We will assume a Beta(1,2) prior, wh ich is prior information 
equivalent to one DLT observed in three treated subjects . Early termination for toxicity will be considered 
based on a posterior probability above 75% that the toxicity rate exceeds 3 0%. A formal dose -limiting toxicity 
(DLT) evalua tion (assessed on day 21) will be done after the first [ADDRESS_730985] DLT (clinically significant, pre -specified AEs), enrollment will continue (posterior probability that 
toxicity rate exceeds 30% is 72%).  If six or more of the first [ADDRESS_730986] DLT, consideration would be given to 
modifying the dose of chemotherapy given in combination with nivolumab (posterior  probability that toxicity 
rate exceeds 30% is 87%).  
 
b) Invasive recurrence -free interval (IRFI)  will be evaluated using Kaplan -Meier analysis.   IRFI will be  
assessed as the time from study entry until diagnosis of the first invasive local, regional, or distant breast 
cancer recurrence during the 24 months after study entry.   
 
Analytic plan for exploratory/correlative objectives:  
 
The association between biom arkers and best overall response (responder versus non -responder primary) 
will be described by [CONTACT_556506], and assessed using the mid -p adju stment to Fisher’s exact 
test. The association between biomarkers and response will be described by [CONTACT_556507] a two -sample t -test with transformation as needed.  
7.[ADDRESS_730987] Population(s) for Analysis  
 
Intent -to-Treat Population (ITT)  
 
The ITT population will include all participants who are enrolled onto the study.  The ITT popula tion will be the 
primary population for evaluating all efficacy endpoints and p articipant  characteristics.  
 
All-Treated Population (AT)  
 
 
S17-[ADDRESS_730988] one dose of study treatment (i.e. 
nivolumab), with treatment assignments designated according to actual study treatment received. The AT 
population will be the primary population for eval uating treatment administration/compliance, safety, and 
efficacy.  
 
8 Safety and Adverse Events  
8.1 Definitions  
 
Unanticipated Problems Involving Risk to Subjects or Others  
 
Any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in nature, severity, or frequency  (i.e. not described in study -related documents such as 
the IRB -approved protocol or consent form, the Investigator’s Brochure  (IB), etc.) 
• Related or possibly related to participation in the research  (i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_9156])  
• Suggests that the r esearch places subjects or others at greater risk of harm  (including physical, 
psycholog ical, economic, or social harm)  
SERIOUS ADVERSE EVENTS  
A Serious Adverse Event (SAE)  is any untoward medical occurrence that at any dose:  
• results in death  
• is life -threatening (defined as an event in which the participant was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused de ath if it were more severe)  
• requires inpatient hospi[INVESTIGATOR_312] (see NOTE  below)  
• results in persistent or significant disability/incapacity  
• is a congenital anomaly/birth defect  
• is an important medical even t (defined as a medical event(s) that may not be immediately life -threatening 
or result in death or hospi[INVESTIGATOR_313], based upon appropriate medical and scientific judgment, may 
jeopardize the subject or may require intervention [eg, medical, surgical] to prevent one of the other 
serious outcomes listed in the definition above.) Examples of such events include, but are not limited to, 
intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do no t result in hospi[INVESTIGATOR_059].)  
• Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the study drug is 
an SAE.  
Although pregnancy, overdose, potential drug -induced liver injury (DILI), and cancer are not always serious 
by [CONTACT_209702], these events must be handled as SAEs.  
Any component of a study endpoint that is considered related to study therapy should be reported as an SAE 
(eg, death is an endpoint, if death occurred due to anaphylaxis, anaphylaxis must be report ed). 
NOTE : (PI [INVESTIGATOR_556450]. This is supplemental information that is included in BMS -sponsored trials)  
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  51 The following hospi[INVESTIGATOR_448212] d SAEs in BMS clinical studies:  
− a visit to the emergency room or other hospi[INVESTIGATOR_20347] < 24 hours, that does not result in admission 
(unless considered an important medical or life -threatening event)  
− elective surgery, planned prior to signing consent  
− admissions as per protocol for a planned medical/surgical procedure  
− routine health assessment requiring admission for baseline/trending of health status (eg, routine 
colonoscopy)  
− Medical/surgical admission other than to remedy ill health and planne d prior to entry into the study. 
Appropriate documentation is required in these cases.  
− Admission encountered for another life circumstance that carries no bearing on health status and 
requires no medical/surgical intervention (eg, lack of housing, economic  inadequacy, caregiver respi[INVESTIGATOR_040], 
family circumstances, administrative reason).  
− Admission for administration of anticancer therapy in the absence of any other SAEs (applies to 
oncology protocols)  
ADVERSE EVENTS  
An Adverse Event (AE) is defined as any new unt oward medical occurrence or worsening of a preexisting 
medical condition in a clinical investigation participant administered study drug and that does not necessarily 
have a causal relationship with this treatment. An AE can therefore be any unfavorable an d unintended sign 
(such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of 
investigational product, whether or not considered related to the investigational product.  
The causal relationship to study drug is determ ined by a physician and should be used to assess all adverse 
events (AE). The casual relationship can be one of the following:  
Related: There is a reasonable causal relationship between study drug administration and the AE.  
Not related: There is not a reasonable causal relationship between study drug administration and the AE.  
The term "reasonable causal relationship" means there is evidence to suggest a causal relationship.  
Adverse events can be spontaneously reported or e licited during open -ended questioning, examination, or 
evaluation of a subject. (In order to prevent reporting bias, subjects should not be questioned regarding the 
specific occurrence of one or more AEs.)  
NONSERIOUS ADVERSE EVENT  
• Non-serious Adverse Event s (AE) are to be provided to BMS in aggregate via interim or final study 
reports as specified in the agreement or, if a regulatory requirement [eg, IND US trial] as part of an 
annual reporting requirement.  
• Non-serious AE information should also be collect ed following the subject’s written consent to 
participate in the study  to establish a baseline status for the subjects.  
A non-serious adverse event  is an AE not classified as serious.  
Non-serious Adverse Event Collection and Reporting  
 
S17-[ADDRESS_730989]’s written consent to participate 
in the study . All non -serious adverse events (not only those deemed to be treatment -related) should be 
collected continuously during the treatment period and for a minimum of [ADDRESS_730990] results that constitute SAEs should be documented and reported to BMS as such.  
The following laboratory abnormalities should be documented and reported appropriately:  
• any laboratory test result that is clinically significant or meets the definition of an SAE  
• any laboratory abnormality that required the participant to have study drug d iscontinued or interrupted  
• any laboratory abnormality that required the subject to receive specific corrective therapy.  
It is expected that wherever possible, the clinical rather than laboratory term would be used by [CONTACT_80582] (e .g., anem ia versus low hemoglobin value).  
8.[ADDRESS_730991] 
be reported are those that are:  
 
• related to study participation,  
• unexpected, and  
• serious or involve risks to subjects or others  
(see definitions, Section 8.1)    
 
Events should be reported using the NYU CTO Medical Events Form. Please email all SAEs to 
[EMAIL_447] , [CONTACT_556531], the NYULMC PCC regulatory specialist, and the Medical 
Monitor [CONTACT_556532] within [ADDRESS_730992] still be reported to the IRB at 
each annual review, either in a summary or tabular format.  
 
8.3.1  Investigator Reporting: Notifying the Study Sponsor  
 
Since  multiple  sites  will be participating,  the following  describes  events  that must  be reported  to the 
study  sponsor  (NYU  Langone  Health  PCC)  and the study sponsor reports to BMS  in an expedited  fashion.  
 
Initial  Report:  within  24 hours:  
The following  events  must  be reported  to the study  sponsor  (NYUL H PCC)  by [CONTACT_556508]  24 hours  of 
awareness  of the event  using  the NYU  CTO  Medical  Events  Form:  
 
• Unanticipated  problems  related  to study  participation,  
• Serious  adverse  events , regardless  of whether  they are unexpected.  
 
The investigator  shall  maintain  a copy  of the Medical  Events  Form  on file at the study  site. All report  
forms  must  be signed  and dated  by [CONTACT_45822].  If the Principal  Investigator  [INVESTIGATOR_556451],  then the form  can be submitted  by a Sub-Investigator.  This 
form should  be reviewed  by [CONTACT_45822],  whom  sign/date  initial  report  upon  return.  
 
Report  to: [EMAIL_2366]  
 
AND  
 
                                                      Maryann Kwa, MD  
                                                      Assistant Professor  of Medicine  
      NYU Perlmutter Cancer Center  
  [ADDRESS_730993], Fourth Floor  
  [LOCATION_001], NY [ZIP_CODE]  
  Tel: (212) 731 -6364  
  Email: [EMAIL_6032]   
 
Events  of Clinical  Interest  (any medical  event  that is deemed  significant  via Principal  Investigator’s  
expertise,  but does  not apply  to SAE  categories)  will be reported  within  2-5 days,  or as per study  
Sponsor  specifications.  
 
Follow -up report:   
As a follow -up to the initial  report,  the investigator  shall  provide  further  information,  as applicable,  on 
the unanticipated event or the unanticipated  problem  in the form of a written  narrative.  This should  
include  a copy  of the completed  Unanticipated  Problem  form,  and any other  diagnostic  information  
that will assist  the understanding  of the event.  
 
Other  Reportable  events:  
 
• Deviations  from  the study  protocol  
Deviations  from the protocol  must  receive  both Sponsor  and the investigator’s  IRB approval  
before  they are initiated.  Any protocol  deviations  initiated  without  Sponsor  and the 
investigator’s  IRB approval  that may affect  the scientific  soundness  of the study,  or affect  
the rights,  safety,  or welfare  of study  subjects,  must  be reported  to the Sponsor  and to the 
investigator’s  IRB as soon  as a possible,  but no later  than  5 working  days  of the protocol  
deviation.  
• Withdrawal  of IRB approval  
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  54 An investigator  shall  report  to the sponsor  a withdrawal  of approval  by [CONTACT_093]’s  
reviewing  IRB as soon  as a possible,  but no later  than  5 working  days  of the IRB 
notification  of withdrawal  of approval  
• All Ser ious Adverse Events (SAEs) that occur following the subject’s written consent to participate in 
the study through  [ADDRESS_730994] be collected that relat e to any 
later protocol -specified  procedure (eg, a follow -up skin biopsy).  
• Following the subject’s written consent to participate in the study, all SAEs, whether related or not 
related to study drug, are collected, including those thought to be associated with protocol -specified 
procedures. The investigator should report any SAE occurring after these aforementioned time periods, 
which is believed to be related to study drug or protocol -specified procedure.  
• An SAE report should be completed for any event whe re doubt exists regarding its seriousness;  
• If the investigator believes that an SAE is not related to study drug,  but is potentially related to the 
conditions of the study (such as withdrawal of previous therapy or a complication of a study procedure), 
the relationship should be specified in the narrative section of the SAE Report Form.  
• If the BMS safety address is not included in the protocol document (eg, multicenter studies where events 
are reported centrally), the procedure for safety rep orting must be reviewed/approved by [CONTACT_556509]. Procedures for such reporting must be reviewed and approved by [CONTACT_556510].  
An appropriate SAE form (e.g. ex-US = CIOMS form or [LOCATION_003] = Medwatch form) should be used to report 
SAEs to BMS.  If you prefer to use your own Institutional form, it must be reviewed by [CONTACT_556511].  Note:  Please include the BMS Protocol number on the SAE form or on the  cover sheet with the 
SAE form transmission.   
o The CIOMS form is ava ilable at: http://www.cioms.ch/index.php/cioms -form-i  
o The MedWatch form is available at: MedWatch 350 0 Form   
 
• For studies with long -term follow -up periods in which safety data are being reported, include the timing 
of SAE collection.  
 
• The Sponsor will reconcile the clinical database SAE cases (case level only) transmitted to BMS 
Global Pharmacovigilance (Worldwid [EMAIL_10578]). Frequency of reconciliation should be 
every 3 months and prior to the database lock or final data summary. BMS GPV&E will email, upon 
request from the Investigator, the GPV&E reconciliation report. Requests for reconciliation should be 
sent to [EMAIL_177]. The data elements listed on the GPV&E reconciliation report 
will be used for case identification purposes. If the Investigator determines a case was not transmitted 
to BMS GPV&E, the case should be sent immediately to BMS .  
 
• In accordance with local regulations, BMS will notify investigators of all reported SAEs that are 
suspected (related to the investigational product) and unexpected (ie, not previously described in the 
IB). An event meeting these criteria is termed a Suspec ted, Unexpected Serious Adverse Reaction 
(S[LOCATION_003]R). Investigator notification of these events will be in the form of a S[LOCATION_003]R Report.  
 
o Other important findings which may be reported by [CONTACT_209705] (ESR) 
include: increased frequency of a  clinically significant expected SAE, an SAE considered 
associated with study procedures that could modify the conduct of the study, lack of efficacy that 
poses significant hazard to study subjects, clinically significant safety finding from a nonclinical 
(eg, animal) study, important safety recommendations from a study data monitoring committee, or 
sponsor decision to end or temporarily halt a clinical study for safety reasons.  
 
S17-[ADDRESS_730995] review and retain the ESR  with the IB. 
Where required by [CONTACT_34342] a central IRB/IEC for the study, the sponsor 
will submit the ESR to the appropriate IRB/IEC. The investigator and IRB/IEC will determine if the 
informed consent requires revision. The inves tigator should also comply with the IRB/IEC 
procedures for reporting any other safety information.  
o In addition to the Sponsor Investigator’s responsibility to report events to their local HA, suspected 
serious adverse reactions (whether expected or unexpe cted) shall be reported by [CONTACT_556512] 
(either as expedited and/or in aggregate reports).  
SAEs, whether related or not related to study drug, and pregnancies mus t be reported to BMS within 24 hours \ 
[ADDRESS_730996] be reported and submitted to BMS on any of the following form(s):  
1. MedWatc h or, CIOMS or  
2. BMS Pregnancy Surveillance Form or,  
3. Approved site SAE form  
* Note : Reporting requirements will vary by [CONTACT_231517].  Please check with your ISR Lead for applicable reporting 
timeframe.  
SAE Email Address:  [EMAIL_176]  
SAE Facsimile Number:  [PHONE_4485] -818-3804  
If only limited information is initially available, follow -up reports are required. (Note: Follow -up SAE reports 
should include the same investiga tor term(s) initially reported.)  
If an ongoing SAE changes in its intensity or relationship to study drug or if new information becomes 
available, a follow -up SAE report should be sent within 24 hours \ [ADDRESS_730997] will be permanently discontinued in an 
appropriate manner (e.g., dose tapering if necessary for partic ipant).  
The investigator must immediately notify [EMAIL_555] of this event via either the CIOMS, 
MedWatch or appropriate Pregnancy Surveillance Form in accordance with SAE reporting procedures.  
Protocol -required procedures for study discontinuation a nd follow -up must be performed on the participant.  
Follow -up information regarding the course of the pregnancy, including perinatal and neonatal outcome and, 
where applicable, offspring information must be reported on the CIOMS, MedWatch, BMS Pregnancy 
Surveillance Form, or approved site SAE form.  A BMS Pregnancy Surveillance Form may be provided upon 
request.  
Any pregnancy that occurs in a female partner of a male study participant should be reported to BMS. 
Information on this pregnancy will be collected  on the Pregnancy Surveillance Form. In order for Sponsor or 
designee to collect any pregnancy surveillance information from the female partner, the female partner must 
sign an informed consent form for disclosure of this information.  
 
S17-[ADDRESS_730998] of care treatment for the respective patient population.  
• Docetaxel injection can cause fetal harm when administered t o a pregnant woman. Female subjects 
/female partners of male subjects should not become pregnant during treatment with docetaxel. Females 
must not breast -feed while being treated with docetaxel. Males being treated with docetaxel are advised 
not to father a child during and up to 6 months after  treatment and to seek advice on conservation of 
sperm prior to treatment because docetaxel may alter male fertility. Use of highly effective contraception 
during treatment is recommended. This drug is classified as F DA Category D, there is positive evidence 
of human fetal risk based on adverse reaction data from investigational or marketing experience or studies 
in humans, but potential benefits may warrant use of the drug in pregnant women despi[INVESTIGATOR_47853].  
• Paclitaxel can cause fetal harm when administered to a pregnant woman. Female subjects /female 
partners of male subjects should not become pregnant during treatment with paclitaxel. Females must 
not breast -feed while being treated with paclitaxel. Males bein g treated with paclitaxel, are advised not to 
father a child during treatment and to seek advice on conservation of sperm prior to treatment because 
paclitaxel may impair fertility. Use of highly effective contraception during treatment is recommended. 
This drug is classified as FDA Category D, there is positive evidence of human fetal risk based on adverse 
reaction data from investigational or marketing experience or studies in humans, but potential benefits 
may warrant use of the drug in pregnant women de spi[INVESTIGATOR_47853].  
• Doxorubicin can cause fetal harm when administered to a pregnant woman. Female subjects /female 
partners of male subjects should not become pregnant during treatment with doxorubicin. Females must 
not breast -feed while being treated with doxorubicin. Doxorubicin may cause infertility in males and 
females. Use of highly effective contraception during treatment and for 6 months after  treatment is 
recommended. This drug is classified as FDA Category D, there is positive evidence of human  fetal risk 
based on adverse reaction data from investigational or marketing experience or studies in humans, but 
potential benefits may warrant use of the drug in pregnant women despi[INVESTIGATOR_47853].  
• Cyclophosphamide can cause fetal harm when administered to pregnant women. Female subjects /female 
partners of male subjects should not become pregnant during treatment with cyclophosphamide. Females 
must not breast -feed while being treated with cyclophosp hamide. Male and female reproductive function 
and fertility may be impaired in patients being treated with cyclophosphamide. Use of highly effective 
contraception during treatment and for up to 1 year after  treatment is recommended. This drug is classified  
as FDA Category D, there is positive evidence of human fetal risk based on adverse reaction data from 
investigational or marketing experience or studies in humans, but potential benefits may warrant use of the 
drug in pregnant women despi[INVESTIGATOR_556452] s. 
• Trastuzumab can cause fetal harm when administered to pregnant women. Female subjects /female 
partners of male subjects should not become pregnant during treatment with trastuzumab. There is no 
information regarding the presence of trastuzumab in human milk, the effects on the breastfed infant, or 
the effects on milk production. Developmental and health benefits of breastfeeding along with the mother's 
clinical need for treatment and any potential adverse effects on the breastfed child from treatment or from 
the underlying maternal condition will be considered by [CONTACT_1963]. This consideration will also 
take into account the trastuzumab wash out period of 7 months. Use of highly effective contraception 
during treatment and for up to 7 months a fter treatment is recommended. This drug is classified as FDA 
Category D, there is positive evidence of human fetal risk based on adverse reaction data from 
investigational or marketing experience or studies in humans, but potential benefits may warrant us e of 
the drug in pregnant women despi[INVESTIGATOR_47853].  
• Pertuzumab can cause fetal harm when administered to pregnant women. Female subjects /female 
partners of male subjects should not become pregnant during treatment with pertuzumab. There is no 
informa tion regarding the presence of pertuzumab in human milk, the effects on the breastfed infant, or 
the effects on milk production. Developmental and health benefits of breastfeeding along with the mother's 
clinical need for treatment and any potential advers e effects on the breastfed child from treatment or from 
the underlying maternal condition will be considered by [CONTACT_1963]. This consideration will also 
take into account the pertuzumab wash out period of [ADDRESS_730999] be reported as an SAE.  
 
8.3.4  Other Safety Considerations  
 
Any significant worsening noted during interim or final physical exami nations, electrocardiograms, imaging 
tests , and any other potential safety asse ssments, whether or not these procedures are required by [CONTACT_12695], should also be recorded as a non -serious or serious AE, as appropriate, and reported accordingly.   
 
8.3.5  Investigator Reporting: N otifying the IRB  
 
Federal  regulations require timely reporting by [CONTACT_556513] .  The following describes the NYULMC IRB reporting requirements, though 
Investigators at participating sites are responsible for meeting the specific  requirements of their local IRB of 
record.  The NYULMC IRB address is:  
 
NYU School of Medicine IRB  
   One Park Avenue, 6th Floor  
   [LOCATION_001], NY [ZIP_CODE]  
 
Report Promptly, but no later than 5 working days:  
 
Researchers are required to  submit reports of the following problems promptly but  no later than  5 working 
days from the time the I nvestigator becomes aware of the event:  
 
• Unanticipated problems including adverse events  that are unexpected and related  
– Unexpected : An event is “unexpected” when its specificity and severity are not accurately reflected 
in the protocol -related documents, such as the IRB -approved res earch protocol, any applicable 
Investigator B rochure, and the current IRB -approved informed consent docu ment and other 
relevant sources of information, such as product labeling and package inserts.   
– Related to the research procedures : An event is related to the research procedures  if in the opi[INVESTIGATOR_556453] S ponsor, the event was more  likely than not to be caused by [CONTACT_118689].   
– Harmful : either caused harm to subjects or others, or placed them at increased risk  
 
Other Reportable events:  
 
The following events  also require prompt reporting  to the IRB , though no later than  5 working days : 
• Complaint of a research subject  when the complaint indicates unexpected risks or the complaint 
cannot be resolved by [CONTACT_5051].  
• Protocol deviations or violations  (includes intentional and accidental/unintentional deviations  from 
the IRB approved protocol) for any of the following situations :  
– one or more participants were placed at increased risk of harm   
– the event has the potential to occur again  
– the deviation was necessary to protect a subject from immediate harm  
• Breach of confidentiality  
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  58 • Incarceration of a participant  when the research was not previously approved under Subpart C a nd 
the Investigator believes it is in the best interest of the subject to remain on the study.  
• New Information indicating a change to the risks or  potential benefits  of the research, in t erms 
of severity or frequency. (e.g. a nalysis indicates lower -than-expected response rate or a more severe 
or frequent side effect; Other research finds arm of study has no therapeutic value; FDA labeling 
change or withdrawal from market)  
 
Reporting Process  
 
The reportable events noted above will be reported to the IRB using the form: “ Reportable Event Form ” or as 
a written report of the event (including a description of the event with information regarding its fulfi llment of 
the above criteria, follow -up/resolution and need for revision to consent form and/or other study 
documentation).  
 
Copi[INVESTIGATOR_556454] a nd receipt will be kept in the Investigator’s study 
file. 
 
8.3.6  Sponsor R eporting: Notifying the FDA  
 
The Study S ponsor is required to report certain study events in an expedited fashion to the FDA.  These 
written notifications of adverse events are referred to as IND safety reports. The following describes the safety 
reporting requirements by [CONTACT_28822]:  
 
• Within 7 calendar days  (via telephone or facsimile report)  
 
Any study event that is : 
– associated with the use of the study drug  
– unexpected,  
– fatal or life -threatening  
 
• Within 15 calendar days  (via written report)  
 
Any study event that is : 
– associated with the use of the study drug,  
– unexpected, and  
– serious, but not fatal or life -threatening  
-or- 
– a previous adverse event that was not initially deemed r eportable but is later found to fit the criteria 
for reporting (reporting within 15 calendar days from when event was deemed reportable).  
 
Additional reporting requirements  
Sponsors are also required to identify in IND safety reports all previous reports c oncerning similar adverse 
events and to analyze the significance of the current event in light of the previous reports.  
 
Reporting Process  
Adverse events may be submitted on FDA Form 3500A or in a narrative format. If supplied as in a narrative 
format, the  minimum information to be supplied is noted above at the beginning of Section 8.[ADDRESS_731000] 
information for submitting IND safety reports is noted below:  
NYU Langone Health Contacts:  
 
[EMAIL_2366]  
 
AND  
 
Maryann Kwa, MD  
NYU Perlmutter Cancer Center  
 
S17-[ADDRESS_731001]  
[LOCATION_001], NY [ZIP_CODE]  
Tel: (212) 731 -6364  
Email: [EMAIL_6032]  
 
8.3.7     Sponsor Reporting: Notifying P articipati ng Investigators  
 
For multi -center trials, it is the responsibility of the Study S pons or to notify all participating I nvestigators of 
any adverse event that meets the FDA 15 -day r eporting requirement criteria . The same materials and timeline 
used to report to the FDA are used for notifying participating Investigators.  
8.4 Medical Monitoring  
 
It is the responsibility of the Principal Investigator [INVESTIGATOR_556455] s/her site.  This safety 
monitoring will include careful assessment and appropriate reporting of adverse events as noted above , as 
well as the construction and implementation of a site data and safety -monitoring plan  detailed below .  Serious 
adverse  events  are evaluated  regularly  by [CONTACT_62674]  [INVESTIGATOR_556456],  the DSMC  is notified  of serious adverse  events  via email  initially,  reviewed  offline  by [CONTACT_556514],  and presented  at the next DSMC  monthly  meeting.  The Data  Safety  and Monitoring  
Committee  (DSMC)  will review  the study  at least  quarterly.  Medical  monitoring  will include  a regular  
assessment  of the number  and type of serious  adverse  events.  
 
8.4.1  Data Safety Monitoring Committee  (DSMC)  
 
This investigator -initiated study will be monitored by [CONTACT_71333] (DSMC) of the 
NYU Perlmutter Cancer Center. The DSMC operates based on the National Cancer Institute approved 
Charter. It is an existing multidisciplinary committee (consisting of clinical investigators/oncologists, 
biostatisticians, nurses, and research administration staff knowledgeable of research methodology and design 
and in proper conduct of clinical trials) that is responsible for monitoring safety, c onduct and compliance in 
accordance with protocol data monitoring plans for clinical trials conducted at the NYU Perlmutter Cancer 
Center that are not monitored by [CONTACT_28827]. The DSMC reports to the Director of the NYU 
Perlmutter Cancer  Center (Benjamin Neel, MD, PhD).  
 
Per the NYU Institutional Data Safety and Monitoring Plan, this phase II trial will be monitored by [CONTACT_556515] (from the date the first subject is enrolled), at protocol -specified interim time points, and at the 
completion of the study prior to study closure. This review includes accrual data, subject demographics and 
adverse events. Principal Investigators are required to attend the review of their studies. Additional reviews 
can be scheduled based on SAE reports , investigator identified issues, external information, etc.  The DSMC 
will review safety data every 3 months.  DSMC summary reports are available to facilitate the review and 
monitoring of this study.    These reports include the following:  subject listi ngs and summary reports that 
describe study enrollment and accrual, eligibility, demographic characteristics, dose modifications, 
adverse experiences, subject’s death and additional external published data if applicable to the study.  
Cumulative toxicities , SAEs, and AEs are reviewed, to identify possible adverse events with elevated 
frequency that is unexpected.  Once a recommendation is made if further action is required, the 
Investigator’s must respond within [ADDRESS_731002] Keepi[INVESTIGATOR_007]  
 
9.1 Confidentiality  
 
The NYU Perlmutter Cancer Center Clinical Trials Office (CTO) together with the PI [INVESTIGATOR_556457].   TrialMaster,  an electronic  database  capture  system  will be created  to 
record  the data for this trial. Research  coordinators  will input  clinical  trial data into the database.  This 
database  is password  protected  and only the PI, assigned  study  team  members,  and CTO  staff 
 
S17-[ADDRESS_731003]  or 
Trial master.  Relevant  source  documentation  to be reviewed  by [CONTACT_556516] : 
1. Baseline  measures  to assess  pre-protocol  disease  status  
2. Concurrent medications  
3. Treatment records  
4. Adverse  events  
 
The study team will maintain clinical and laboratory data in a designed manner to ensure patient 
confidentiality. All study personnel have passed human subject protection courses. If applicable, tissue 
samples sent to collaborators outside of NYU will only  be labeled with an assigned protocol -patient 
identification number without patient identifiers. Systems used for electronic data capture are compliant with 
FDA regulations in [ADDRESS_731004] of 1996 (HIPAA).  Those regulations require a signed 
subject authorization informing the subject  of the following:  
 
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information   
• The rights of a research subject to revoke their auth orization for use of their PHI  
 
In the event that a subject revokes authorization  to collect or use PHI, the I nvestigator, by [CONTACT_5151], retains 
the ability to use all information collected prior to the revocation of subject authorization.  For subjects t hat 
have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at 
least vital status (i.e. that the subject is alive) at the end of their scheduled study period.  
9.3 Source Documents  
 
Source data is all informatio n, original records of clinical findings, observations, or other activities in a clinical 
trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in source 
documents.  Examples of these original documents, and data re cords include: hospi[INVESTIGATOR_1097], clinical and 
office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, copi[INVESTIGATOR_556458], microfiches, photographic negatives, microfilm or magnetic media, x -rays, 
subject files, and records kept at the pharmacy, at the laboratories, and at medico -technical departments 
involved in the clinical trial.  
9.4 Records R etention  
 
It is the I nvestigator’s responsibility to retain study essential documents for at least [ADDRESS_731005].  These documents should be retained for a longer period if 
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  61 required by [CONTACT_315192] S ponsor.  In such an instance, i t is the responsibility of the Sponsor to 
inform the Investigator/I nstitution as to when these documents no longer need to be retained.   
 
[ADDRESS_731006]  will review  various  aspects  of the trial including,  but not limited  to: screening  and 
enrollment  logs;  compliance  with the protocol  and with the principles  of Good  Clinical  Practice;  
completion  of case  report  forms;  source  data verification;  study  drug accountability  and storage.  
 
During  scheduled  monitoring  visits,  the investigator  and the investigational  site staff must  be available  
to meet  with the quality  assurance  specialist  in order  to discuss  the progress  of the trial, make  necessary  
corrections  to case  report  form  entries,  respond  to data clarification  requests  and respond  to any other  
trial-related  inquiries  of the monitor.  In addition  to on-site monitoring  visits,  the Sponsor  and/or  
representatives  will also be routinely  reviewing  data.  Any queries  identified  through  this review  will be 
managed  within  the systems  established  for query  resolution  and tracking.  Inquiries  related  to study  
conduct,  which  require  further  information  or action  will be discussed  within  the study  team  for 
appropriate  and documented  escalation  plans.  It is expected  that response  to data clarification  requests  
and other  trial-related  inquiries  will occur  throughout  the course  of the study  through  regular  
communication  with the site monitor,  the Sponsor  or representatives,  and review/entry  of data into the 
electronic  study  database.  
 
At any time during  the course  of the study,  representatives  of the FDA  and/or  local  regulatory  agencies  
may review  the conduct  or results  of the study  at the investigational  site. The investigator  must  promptly  
inform  NYU  PCC  CTO  and BMS  of any audit  requests  by [CONTACT_556517],  and will provide  BMS  with 
the results  of any such  audits  and with copi[INVESTIGATOR_556459].  
 
In accordance  with HIPAA  and associated  privacy  regulations,  a patient’s  authorization  to use personal  
identifiable  health  information  may be required  from each  patient  before  commencement  of research  
activities.  This authorization  document  must  clearly  specify  what  parties  will have  access  to a patient’s  
personal  health  information,  for what  purpose  and for what  duration.  
 
At the NYU  Perlmutter  Cancer  Center,  all investigator -initiated  protocols  are subject  to a standardized    
data and safety  monitoring,  which  includes  scientific  peer  review,  IRB review  and DSMC  review  as well 
as internal  auditing.  
 
The review  of AEs and trial conduct  for this trial occurs  at several  levels:  
 
(1) Principal  Investigator:  [INVESTIGATOR_556460],  data manager  and research  team.  
 
(2) DSMC,  quarterly  
 
(3) Institutional  Review  Board  (IRB):  An annual  report  to the IRB is submitted  by [CONTACT_28831] 
[INVESTIGATOR_556461].  It includes  a summary  of all AEs,  total enrollment  with 
demographics,  protocol  violations,  and current  status  of subjects  as well as available  
research  data.  
 
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  62 In addition,  the quality  assurance  unit will monitor  this trial every  4-6 weeks,  this includes  real-time review  
of all eCRFs  to ensure  completeness  and to verify  adherence  to the protocol;  the completeness,  
accuracy  and consistency  of the data;  and adherence  to ICH Good  Clinical  Practice  guidelines.  
Additionally,  a first subject  audit  is to be conducted  within  four weeks  of enrollment . 
10.2 Auditing and Inspecting  
 
The I nvestigator will permit study -related monitoring, audits, and inspections by [CONTACT_1201]/Ethics Committee 
(EC), the S ponsor, government regulatory bodies, and University compliance and quality assurance groups 
of all study related documents (e.g. source docume nts, regulatory documents, data collection instr uments, 
study data etc.).  The I nvestigator will ensure the capability for inspections of applicable study -related facilities 
(e.g. pharmacy, diagnostic laboratory, etc.).  
 
Participation as an I nvestigator in  this study implies acceptance of potential inspection by [CONTACT_556518] e and quality assurance offices.  
 
 
[ADDRESS_731007] (IRB) 
or independent  Ethics Committee (EC) in agreement with local legal prescriptions, for formal approval of the 
study conduct.  The decision of the IRB/EC concerning the conduct of the study will be made in writing to the 
Investigator and a copy of this decision will be pr ovided to the Sponsor before commencement of this study.  
The Investigator should provide a list of IRB/EC members and their affiliate to the Sponsor.  
 
All subjects for this study will be provided a consent form describing this study and providing sufficient 
information for subjects to make an informed decision about their participation in this study.  This consent 
form will be submitted with the protocol  for review and approval by [CONTACT_1201]/EC for the study.  The formal 
consent of a subject, using the IRB/EC -approved consent form, must be obtained before that subject 
undergoes any study procedure.  The consent form must be signed by [CONTACT_556519] a cceptable 
surrogate, and the investigator -designated research professional obtaining the consent.  
 
[ADDRESS_731008] with this study (patent ownershi p, royalties, or financial gain 
greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by a properly 
constituted Conflict of Interest Committee with a Committee -sanctioned conflict management plan that has 
been revie wed and approved by [CONTACT_71392] S ponsor prior to participation in this study.  All NYULH  investigators 
will follow the  applicable  Univer sity conflict of interest policies . 
 
[ADDRESS_731009] 
carcinoma incidence and survival: the surveillance, epi[INVESTIGATOR_623], and end results program at the National 
Cancer Institute. J Natl Cancer Inst 2005;97:[ADDRESS_731010]. 2nd ed. Philadelphia: Saunders, 2nd ed.; 1971.  
3. Matro JM, Li T, Cristofanilli M, et al. Inflammatory breast cancer management in the national 
comprehensive cancer network: the disease, recurrence pattern, and outcome. Clin Breast Canc er 2015;15:[ADDRESS_731011] Cancer  Res Treat 2012;134:[ADDRESS_731012] cancer: a proposed conceptual shift 
in the UICC -AJCC TNM staging system. Lancet Oncol 2017;18:e228 -e32. 
6. Ueno NT, Espi[INVESTIGATOR_556462], Cristofanilli M, et al. International Consensus on the Clinical 
Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research 
Program 10th Anniversary Conference. J Cancer 2018;9:1437 -47. 
7. National Comprehensive Cance r Network (NCCN) Clinical Practice Guidelines in Oncology. Breast 
Cancer, version 1.[ADDRESS_731013] carcinom a. Ann Surg Oncol 1997;4:[ADDRESS_731014] cancer: the M. D. Anderson Cancer 
Center experience. Clin Breast Cancer 2004;4:[ADDRESS_731015] carcinoma axillary lymph 
node metastases after primary systemic chemotherapy. Cancer 2006;106:1000 -6. 
12. Dethlefsen L, McFall -Ngai M, Relman DA. An ecological a nd evolutionary perspective on human -
microbe mutualism and disease. Nature 2007;449:[ADDRESS_731016] cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2 -
negative cohort. Lancet 2010;375:[ADDRESS_731017] cancer 
(NeoSphere): a randomised multicentre, open -label, phase 2 trial. Lancet Oncol 2012;13:[ADDRESS_731018] 
cancer by [CONTACT_556520] - and HER2 -defined subtypes. Ann Oncol 2014;25:[ADDRESS_731019] cancer: a 
hyperproliferative phenoty pe. Clin Cancer Res 2006;12:[ADDRESS_731020] cancer (IBC): analysis of 
2,[ADDRESS_731021] Cancer Res 2009;11:R9.  
18. Loi S, Sirtaine N, Pi[INVESTIGATOR_34413] F, et al. Prognostic and predictive value of tumor -infiltrating lymphocytes in a 
phase III randomized adjuvant breast cancer trial in node -positive br east cancer comparing the addition of 
docetaxel to doxorubicin with doxorubicin -based chemotherapy: BIG 02 -98. J Clin Oncol 2013;31:[ADDRESS_731022] cancer trials: ECOG 2197 and ECOG 
1199. J Clin Oncol 2014;32:[ADDRESS_731023] cancer: results from the FinHER trial. Ann 
Oncol 2014;25:[ADDRESS_731024] cancer (IBC) and patterns of 
recurrence: understanding the biology of a unique  disease. Cancer 2007;110:[ADDRESS_731025] Cancer. N Engl J Med 2018;379:[ADDRESS_731026] cancer is frequent and 
predicts for the pathological response to chemotherapy. Oncotarget 2015;6:[ADDRESS_731027] ion. Nat Immunol 2007;8:239 -45. 
25. Nonclinical Study Report: Medarex Study No. MDX1106 -025-R.  In vitro characterization of fully 
human anti -PD-1 monoclonal antibody.  Bristol -Myers Squibb Company; 2007.  Document Control No: 
930046580.  
26. Nonclinical St udy Report: Medarex Study No. MDX1106 -028-R.  Binding and blocking characteristics 
of chimeric anti -mouse PD -1 antibody, 4H2.  Bristol -Myers Squibb Company; 2007.  Document Control No: 
930046578.  
27. Nonclinical Study Report: Medarex Study No. MDX1106 -023-R.  Effect of anti -PD-1 monoclonal 
antibody administration on unstaged MC38 tumor growth rates in mice.  Bristol -Myers Squibb Company; 
2006.  Document Control No: 930046542.  
28. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti -PD-1 antibody nivolumab, 
BMS -936558, and in vivo toxicology in non -human primates. Cancer Immunol Res 2014;2:846 -56. 
29. BMS -936558: Intravenous Study of pre - and postnatal development in cynomolgus monkeys with a 6 -
month postnatal evaluation. Final report for S tudy DN12001. Bristol -Myers Squibb Company; Document 
Control No: 930073964.  
30. Ueno NT, Buzdar AU, Singletary SE, et al. Combined -modality treatment of inflammatory breast 
carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemo ther Pharmacol 
1997;40:[ADDRESS_731028] cancer limits 
interpretation of treatment outcomes: a systematic review. Clin Breast Cancer 2006;7:[ADDRESS_731029] cancer (NOAH): follow -up of a randomised controlled superiority trial 
with a parallel HER2 -negative cohort. Lancet Oncol 2014;15:[ADDRESS_731030] cancer: a randomized phase II cardiac saf ety study (TRYPHAENA). Ann Oncol 
2013;24:2278 -84. 
34. Schneeweiss A, Chia S, Hickish T, et al. Long -term efficacy analysis of the randomised, phase II 
TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant 
anthracyc line-containing and anthracycline -free chemotherapy regimens in patients with HER2 -positive early 
breast cancer. Eur J Cancer 2018;89:[ADDRESS_731031] Cancer. N Engl J Med 2017;377:[ADDRESS_731032] cancer. Semin Oncol 2008;35:[ADDRESS_731033] cancer (BEVERLY -1): a multicentre, single -arm, phase 2 study. Lancet 
Oncol 2016;17:[ADDRESS_731034] cancer (BEVERLY -2): an open -label, single -arm phase 2 study. 
Lancet Oncol 2012;13:[ADDRESS_731035] FC, Autret A, et al. Circulating tumour cells and pathological complete response: 
independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II 
trials (BEVERLY -1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol 
2017;28:[ADDRESS_731036] cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet 
Oncol 2014;15:[ADDRESS_731037] of the addition of carboplatin and/or bevacizumab to 
neoadjuvant once -per-week paclitaxel followed by [CONTACT_2715] -dense doxorubicin and cyclophosphamide on 
pathologic complete response rates in stage II to III triple -negative breast cancer: CALGB [ZIP_CODE] (Alliance) . J 
Clin Oncol 2015;33:[ADDRESS_731038] cancer (BC): Results from I -SPY 2. J Clin Oncol 35, 2017 (suppl; abstr 506).  
44. Schmid P, Park, YH, Munoz -Couselo, E, e t al. Pembrolizumab + chemotherapy as neoadjuvant 
treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE -173. J Clin Oncol 35, 
2017 (suppl; abstr 556).  
45. Loibl S, Untch, M, Burchardi, N, et al. A randomized phase II neoadjuv ant study (GeparNuevo) to 
investigate the addition of durvalumab, a PD -L1 antibody, to a taxane -anthracycline containing chemotherapy 
in triple negative breast cancer (TNBC). J Clin Oncol 35, 2017 (suppl; abstr 3062)  
46. Loibl S, Untch, M, Burchardi, N, e t al. Randomized phase II neoadjuvant study (GeparNuevo) to 
investigate the addition of durvalumab to a taxane -anthracycline containing chemotherapy in triple negative 
breast cancer (TNBC).  . J Clin Oncol 36, 2018 (suppl; abstr 104).  
47. Pusztai L, Silber , A, Wysong Hofstatter, E, et al. Safety of MEDI4736 (anti -PD-L1 antibody) 
administered concomitant with weekly nab -paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) 
as neoadjuvant chemotherapy for stage I -III triple negative breast cancer (TNB C): A Phase I/II trial. J Clin 
Oncol 35, 2017 (suppl; abstr 572).  
48. Loi S, Giobbe -Hurder, A, Gombos, A, et al. Phase Ib/II study evaluating safety and efficacy of 
pembrolizumab and trastuzumab in patients with trastuzumab -resistant HER2 -positive metastat ic breast 
cancer: Results from the PANACEA (IBCSG 45 -13/BIG 4 -13/KEYNOTE -014) study. [ADDRESS_731039] 
Cancer Symposium (SABCS). Abstract GS2 -06. 
49. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2 -
Positive  Breast Cancer. N Engl J Med 2019;380:[ADDRESS_731040] Cancer after Preoperative 
Chemotherapy. N Engl J Med 2017;376:[ADDRESS_731041] -line treatment for 
advanced non -small -cell lung cancer (CheckMate 012): results of an open -label, phase 1, multicohort study. 
Lancet Oncol 2017;18:[ADDRESS_731042] cancer (mTNBC). J Clin Oncol 34, 2016 (suppl; 
abstr 1009).  
54. Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, et al. Comparisons between 
different polychemotherapy regimens for early breast cancer: meta -analyses of long -term outcome among 
100,000 women in 123 randomised  trials. Lancet 2012;379:432 -44. 
55. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical 
Adjuvant Breast and Bowel Project Protocols B -18 and B -27. J Clin Oncol 2008;26:[ADDRESS_731043] cancer:National Surgical Adjuvant 
Breast and Bowel Project Protocol B -27. J Clin Oncol 2006;24:[ADDRESS_731044] cancer. J Clin Oncol 
2004;22:[ADDRESS_731045] cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:[ADDRESS_731046] cancer (Neo -tAnGo): an open -label , 2x2 factorial randomised phase 3 trial. Lancet Oncol 
2014;15:201 -12. 
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  67 60. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of 
American Pathologists guideline recommendations for immunohistochemical testing of estrogen and 
progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:[ADDRESS_731047] cancer: American Society of Clinical Oncology/Colleg e of American Pathologists 
clinical practice guideline update. Arch Pathol Lab Med 2014;138:[ADDRESS_731048] cancer biology: the 
tumour microenvironment is key. Nat Rev Cancer 2018.  
63. Arias -Pulido H, Cimino -Mathews A, Chaher N, et al. The combined presence of CD20 + B cells and 
PD-L1 + tumor -infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient 
outcome. Breast Cancer Res Treat 2018.  
64. Valeta -Magara A, Gadi A, Volta V, et al. Inflammatory Breast Cancer Promotes Development of M2 
Tumor -associated Macrophages and Cancer Mesenchymal Cells Through a Complex Cytokine Network. 
Cancer Res 2019.  
65. Jhaveri K, Teplinsky E, Silvera D, et al. Hype ractivated mTOR and JAK2/STAT3 Pathways: Molecular 
Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After 
Neoadjuvant Chemotherapy. Clin Breast Cancer 2016;16:113 -22 e1.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  68 16   Appendices  
 
Appendix 1: Guidelines for Sub -site Institutions in Multi -Center Studies  
 
1. Multi -site Communication  
 
The Clinical Trials Office (CTO) at NYU Permutter Cancer Center (PCC) provides administration, data 
management, and organizational support for the affiliate sites in the conduct of a multicenter clinical trial. The 
CTO office will coordinate  regularly sche duled conference calls with affiliate sites.  
 
2. Regulatory Documents  
 
Prior to Site Initiation:  
 
Regu latory documents may be sent to: PCC -[EMAIL_10577]  
 
3. Central Registration Procedures: Sub-site Institution Research Participant Registration 
Process  
 
All sub-site Institutions must register subjects wi th the coordinating center (NYULH ) prior to any 
administration of study drug/intervention/local institution registration.  Please see instructions below:  
 
Enrollment at additional sites can begin once each site’s IRB has approved this protocol, a copy of each site’s 
IRB approval, Citi training certificates, Medical Licenses and signed CVs are provided to NYU La ngone Health 
Perlmutter Cancer Center (PCC) Clinical Trials Office.  Once, all required documents are provided to NYU 
Clinical Trials Office an activation notification will be sent to the PI [INVESTIGATOR_556463].  Central 
registration for this study will take place at NYU Langone Health PCC Quality Assurance Unit ( PCC -
[EMAIL_10577] ).  
 
Each  patient  must  sign and date an informed  consent  form  before  undergoing  any study  specific  
procedures  unless  a procedure  is being  performed  as part of the patient’s  standard  of care.  Once  a 
patient  has signed  consent,  each  site must  notify  the NYU  Langone  Health  PCC  Quality  Assurance  Unit 
and forward  a copy  of the signed  consent  to NYU  Langone  Health  PCC  Clinical  Trials  Office  within  24 
hours.  
 
1.  Within 24 hours of obtaining consent (excluding holidays and weekends), the sub-site Institution CRN and/or 
CRC is required to submit the following documents  via email ( PCC -QAU@nyu langone .org), with a request to 
register the patient “pending eligibility”  to the NYULH ’s Clinical Trials Office, Quali ty Assurance Unit. . The 
documents will be reviewed for accurateness, and subsequent ly the patient will be registered.   
 
2.  Registration  will occur  once  the Senior  Research  Nurse  for Quality  Assurance  conducts  a central  
review  of the submitted  materials.  Once  eligibility  is verified,  a unique  subject  study  number  will be 
issued  within  [ADDRESS_731049]’s  unique  
study  number.  
  
3.  The subject  will not be identified  by [CONTACT_2300].  This is the point,  at which,  the patient  is considered  
accrued  on study.  Protocol  treatment  should  begin  within  designated  timeframe;  issues  that  would  
cause  treatment  delays  should  be discussed  with the overall  PI, Dr. K w a . All screen  
failures/ineligible  subjects,  as well as subject’s  who withdraw  consent  prior  to initiation  of protocol  
therapy  must  be submitted  to the CTO  in a manner  analogous  to the procedures  noted  above.  
Applicable  source  documentation  will be required  within  the corresponding  submissions.  
 
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  69 4.   Each  site is responsible  for reporting  all unexpected  problems  involving  risks  to participants  or others  
to NYU  Langone  PCC  Clinical  Trials  Office  and to their IRB as per site institutional  policy.  
 
5.  Please  email  all SAEs  to [EMAIL_2366] , [CONTACT_306290], and the NYU  Langone  
Health  QA Unit ( PCC -QAU@nyu langone .org) . 
 
4.  Protocol Deviation/Subject Waiver Request for Sub-sites  
 
The sub-site MUST submit a prospective deviation request to the NYULH  lead PI  [INVESTIGATOR_556464]. Approvals must be obtained from all entities prior to implementation at the Sub-site. If a 
prospective protocol deviation request is submitted for review (from a sub -site), the PI/site memo(s), NYU  
DSMC approval(s) and correspon dence and NYU  IRB eligibility deviation approval letter(s) should be forwarded 
to the sub-site for documentation. The sub-site is also required to obtain prospective local IRB approval as per 
institutional policies/procedures prior to implementing the prop osed deviation and registe ring/enrolling the 
subject via NYULH  Central Registration. All documents and determinations must be clearly documented in the 
study subject’s medical record, research chart and regulatory binder, as described.  
 
5.  Guidelines for  Monitoring  
 
An SIV (or) teleconference will be scheduled and conducted prior to study drug being made available (if 
applicable) and before any subjects are enrolled on a study at the  external  site.  
 
Monitoring visits  are done  remotely  unless  otherwise  specified,  via remote  EMR  access.  If not possible,  
secure  email  exchange  will be utilized.  The quality  assurance  specialist  will confirm  an upcoming 
monitoring visit  with a sub-site Investigator  and staff.  If remote  EMR  access  is not available,  then the sub-
site Coordinator  will ensure  that all source  documents  for subjects  are de-identified  and labeled  only with 
the subject  ID number(s),  and emails  all requested  documents  to the quality  assurance  specialist  by [CONTACT_556521].  All documents  are reviewed  and a monitoring  report  is submitted  within  [ADDRESS_731050]  for the next monitoring  visit.  It is expected  that response  to data clarification  requests  and other  
trial-related  inquiries  will occur  throughout  the course  of the study  through  regular  communication  with the 
site monitor,  the Sponsor  or representatives,  and review/entry  of data into the electronic  study  database.  
Continued  non-compliance  and failure  to submit  documentation  will result  in the suspension  of subject  
enrollment  at the site, until the documents  have  been  received.  
 
1. External  sites will be monitored by [CONTACT_556522] a regulatory level, as well as a clinical 
data/source documentation review level.  
2. Redacted source documents (applicable to supporting the protocol specific CRF data requirements) will be 
sent to the  designated QA Specialist  via secure email for all subjects enrolled at external  sites. Timelines for 
submission procedures will be defined on a case -by-case basis.  
3. The QA Specialist  will review all submitted redacted source documents against the data entered on the 
protocol specific CRFs. The QA Specialist  will issue queries when/if necessary.  
4. The external  site research staff will respond to queries within the designated time fra me (response times vary 
based on trial risk) . If queries remain outstanding, the QA Specialist  will send a delinquent query reminder for 
the outstanding items.  
5. The remote monitoring procedures will include review of applicable redacted source documenta tion and 
supporting applicable documents to determine compliance regarding:  
 
• Informed consent procedures  
• Eligibility criteria  
• Protocol specific treatment compliance  
• Protocol specific toxicity/outcome documentation/compliance  
• Protocol specific schedule  of events (e.g., baseline visits, pre -treatment, on study, follow -up)  
• Participating site IRB documents (e.g., IRB amendment approvals, annual renewals, SAE/UP 
submissions, violation/deviation submissions, INDSR submissions, etc.).  
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  70 • Required specimen submissions (e.g., tissue specimens, research blood specimens, etc.)  
• Pharmacy accountability records  
• Adherence to the CRF submission timeframes to NYU LH (within the protocol specified timeframes)  
 
6. External  site remote monitoring rep orts will be sent to the lead PI, NYULH  DSMC, and sub-sites after each 
remote monitoring review. Reports will include information regarding data submission timeliness/accuracy, 
protocol adherence items, query resolution status, regulatory status, and overa ll site performance. These 
reports will be generated by [CONTACT_556523].  
 
6. Dose Level Determinations  
 
The Sponsor -Investigator/S tatistician will review enrollment for each dose level cohort durin g the regularly 
scheduled conference call with the sub-sites.  
 
The dose level for newly enrolled subjects will be determined by [CONTACT_187048] a 
subject has signed informed consent to participate in the study. The assigned dose level for any subject to 
begin study treatment will be commu nicated to the affiliate site along with the determination by [CONTACT_556524].  
 
If a Dose Limiting Toxicity (DLT) is identified in a subject, the affiliate site must notify the Sponsor -Investig ator 
via email at the study specific email address within [ADDRESS_731051] being assigned the next 
sequential number (e.g. 04 -10). All sites will be required to enter their data in the designate d electronic data 
capture Clinical Trial Management System used for all c ancer -related clinical research at NYUL H. All users 
must login with their own application username [CONTACT_2383]. Users off campus must first access the NYULMC 
Portal  with their assign ed campus username [CONTACT_141846].  
 
Subject confidentiality must be maintained according to HIPAA regulations and GCP recommendations.  
Except when required by [CONTACT_2371], study information shared with persons and organizations outside of NYULH must 
not identify the patient by [CONTACT_2300], social security  number, address, telephone number, or any other direct 
personal identifier.  
 
If the results of this research project are published or presented at a scientific or medical meeting, the patient 
not be identified. Otherwise, all results will be kept confide ntial and will not be divulged (except as required by 
[CONTACT_2371]) without permission.  
 
8.  Data Reporting Plan  
 
NYULH  is deeply committed to research integrity and strong credibility when it comes to the discovery of new 
treatment concepts, implementation of new clinical research techniques, and acceptance of its researcher's 
findings by [CONTACT_187050]. In acc ord with these ethics, NYULH  encourages and supports its 
investigators in the sharing of final research data and/or details of newly developed clinical treatments.  
 
NYULH 's policies that pertain to patient data sharing conform to NYU  IRB rules, local and state laws, and HIPAA 
privacy regulations. The primary reason for this is to protect the privacy of patients who participate in clinical 
trials. The data can be made available for continuing review by [CONTACT_556525], Statistician, Data Safety and Monitoring Board (DSMC), and, 
in other instances, the NYU  IRB. 
 
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  71 Data collected during the course of this clinical trial will primarily be shared with other investigators and 
Universit y staff, the IRB, FDA, and other reporting agencies, and/or transferred to other collaborators. Prior to 
transfer, the data collected must comply with, and must be limited by, the NYULMC 's guidelines for Protecting 
the Rights and Privacy of Human Subjects.   
 
9.  Data Acquisition and Submission  
 
Informed consent, including HIPPA authorization, must be obtained on all subjects prior to their participation. 
Always keep the original signed and dated consent form, with the redacted source documents and eligibil ity 
checklist. A designated electronic data capture system  will be used as the electronic clinical trials and data 
management system. Affiliate sites will enter data directly into the system  via customized case report forms for 
the study. The research staf f will generate reports from the designated electronic data capture system  to ensure 
timely submission of data by [CONTACT_141839]. This resource allows for the timely analysis of particular data sets 
for safety analysis.  
 
 
  
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  72 Appendix 2:  Eastern Cooperative Oncology Group (ECOG) Performance Status 
Criteria  
 
 
Description  Grade  
Fully active, able to carry on all pre -disease 
performance without restriction  
 0 
Restricted in physically strenuous activity, but 
ambulatory and able to carry out work of a light or 
sedentary nature ( i.e., light house work, office 
work )  
 1 
Ambulatory and capable of all self -care but unable 
to carry out any work activities. Up and abo ut more 
than 50% of waking hours.  
 2 
Capable of only limited self -care, confined to bed or 
chair  more than 50% of waking hours  
 3 
Completely disabled. Cannot carry on any self -
care. Totally confined to bed or chair.  4 
Dead  
 5 
 
 
  
 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  73 Appendix 3:  Management A lgorithms for Investigational Agent, Nivolumab   
 
These general guidelines constitute guidance to the Investigator and may be supplemented by [CONTACT_556526].  The guidance applies to all immuno -oncology agents and regimens.  
 
A general principle is that different diagnoses should be diligently evaluated according to standard medical 
practice.  Non -inflammatory etiologies should be considered and appropriately treated.   
 
Corticosteroids are a primary therapy for immuno -oncology drug -related adverse events. The oral equivalent of 
the recommended IV doses may be considered for ambulatory patients with low -grade toxicity. The lower 
bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral 
corticosteroids.  
 
Consultation with a medical or surgical specialist, especially prior to an invasive diagnostic or therapeutic 
procedure, is recommended.  The frequency and severity of the related adverse events covered by [CONTACT_556527] -oncology agent or regimen being used.  
 
 
 
 
 

 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  74  
 

 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  75  
 

 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  76  

 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  77  

 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  78  
 

 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  79  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  80 Appendix 4 : Asymptomatic D ecline in LVEF: Algorithm for Continuation and 
Discontinuation of Treatment with Trastuzumab, and/or Pertuzumab  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
S17-[ZIP_CODE]  
Version 6.0    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_120776].  81 Appendix 5: 
 
NYU/Bellevue Clinical Co -Investigators:  
Sylvia Adams, MD  
Yelena Novik, MD  
James Speyer, MD  
Ruth Oratz, MD  
Marleen Meyers, MD  
Franco Muggia, MD  
Jennifer Wu, MD  
Arjun Iyengar, MD  
MaryLynn Nierodzik, MD  
Amber Guth, MD  
Deborah Axelrod, MD  
Freya Schnabel, MD  
Karen Hiotis, MD  
Richard Shapi[INVESTIGATOR_2152], MD  
Kathie -Ann Joseph, MD  
 
NYU Laboratory Co -Investigators:  
Robert Schneider, PhD  
Paolo Cotzia, MD  
Matija Snuderl, MD  
Pratip Chattopadhyay, PhD  
 
NYU Biostatistician Co -Investigator:  
Andrea B. Troxel, ScD  
 
Indiana University Clinical Co -Investigator:  
Kathy Miller, MD  
 